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Receptors are (macro) molecules occurring in the cell membrane, in the
cytoplasm (soluble receptors) of the cell, and in the cell nucleus, and are
capable of binding a distinct chemical entity, after which the information
present in that entity is transduced to the cell, thereby regulating a variety of
biochemical processes necessary for the cell (and the organism) to function and
survive. Both naturally occurring and synthetic molecules could serve as these
chemical entities. Hormones, neurotransmitters and drugs are well-known
examples of such (pharmacological active) receptor-binding substances.
For the qualitative and/or quantitative analysis of these substances, several
methods are available, including separation methods, such as high performance
liquid chromatography (HPLC). A special place among all methods available in
biopharmaceutical analysis is taken by the receptor assay (RA). Receptor
assays are, like immunoassays (IA), ligand-binding assays in which there is a
competition between an analyte (e.g. the unknown quantity of drug in a blood-
or urine sample) and a (labeled) ligand for binding to the same binding site, the
receptor or antibody, respectively.
There are several advantages of RA over IA:
1. Substances belonging to the same pharmacological class can be
determined, which includes active metabolites. Moreover, from
enantiomeric substances, only the eutomer will bind to the receptor and,
thus, can be detected. Cross-reactivity, one of the major problems
encountered when antibodies are used, is not an issue in RA. Therefore,
RA is a selective technique.
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2. There is a direct correlation between pharmacological potency of a drug
and the limit of detection (LOD). In other words, highly potent drugs that
will be administered in low dosages, and thus are present in low
concentrations in the biological matrix, can be detected easily because of
their high affinity, and vice versa. Therefore, RA is a sensitive technique.
3. Receptors can be isolated relatively simply from animal tissue (e.g. brain
tissue), which is often abundantly available from the slaughterhouse. In
contrast, IA requires a complicated, costly production procedure because of
the use of antibodies.
The binding of a ligand to its receptor can be detected by the use of a suitable
label. Radioactive isotopes have become popular, due to the high sensitivity
that can be obtained, and because the structure of the ligand will (in most cases)
not be affected by the presence of  the isotope (mainly 3H).
However, the disadvantages of using radioactive materials are obvious.
Therefore, alternative labels have been developed for the use in receptor assays.
So far, the approach has been to use mainly fluorescent labeling of ligands for a
variety of receptors. Since fluorophores generally are relatively large
molecules, as a consequence, the labeling of the ligand in many cases causes a
decrease in the binding affinity of the ligand for its receptor, due to e.g. steric
hindrance.
To circumvent this problem, a different approach was used, as described in this
thesis.
The basic idea is to label the receptor indirectly by incorporating the receptor
protein in liposomes containing fluorescent functionalities. In order to obtain a
competition assay, a ligand should be used allowing separation of protein
liposomes which are either bound to the analyte or present in a different form
(free or bound to the label).
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For practical reasons and future automation it was decided to immobilize a
ligand on the surface of wells of microtiter plates. For that purpose, the receptor
has to be isolated from the (other) membrane (constituents) and reconstituted
into liposomes. We used the benzodiazepine receptor as a model, because of
our experience with fluorescent-ligand receptor assays for benzodiazepines. As
a first step, we needed a suitable solubilization procedure to isolate the receptor
from the brain membranes. Deoxycholic acid was chosen because of its ability
to solubilize the benzodiazepine receptor in large amounts. Optimal incubation
conditions were found by varying the concentration of detergent, the ionic
strength and the pH of the incubation mixture.
Secondly, solubilized receptors had to be reconstituted in liposomes. Because
exposure to detergents should be kept to a minimum, to avoid denaturation of
the receptors, a fast procedure for the reconstitution was needed. Therefore, we
preferred gelfiltration over dialysis. Several lipids and lipid combinations were
used to obtain a proteoliposome suspension in which the benzodiazepine
receptor displayed optimal binding characteristics with respect to affinity
(measured as Kd) as well as the maximum amount of binding sites (Bmax).
Furthermore, the effect of freezing and thawing of the proteoliposome
suspension on the binding parameters was examined, since freezing and
thawing leads to an increase in the average size of the proteoliposomes, which
might be favorable for the accommodation of large receptor proteins in the
(phospho)lipid bilayers.
For the development of the fluorescent receptor assay, a ligand had to be
immobilized to a solid phase. It is important that, after immobilization, the
ligand retains its high affinity for the receptor. Didesethylflurazepam was
chosen for the immobilization since it had been used previously for
immobilization to agarose beads (with retention of high affinity) for affinity
purification of the benzodiazepine receptor. The same protocol could be used
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with only minor modifications. Maleic anhydride activated microtiter plates,
normally used for the immobilization of proteins for e.g. immunoassays, were
suitable for coupling of the ligand, because of the abundance of reactive
groups.
The detection of the binding of the receptor-proteoliposomes to the
immobilized ligands was accomplished by a modified radioreceptor assay, or
by incorporating fluorescent lipids into the proteoliposomes. The use of
fluorescent lipids has the advantage that many labels can be incorporated per
single receptor molecule, thereby increasing the detection ability, and
consequently the sensitivity of the actual assay. Other types of label were
considered (e.g. chemiluminescent labels or enzymes), but these have the
disadvantage that an additional step is required for detection.
For accurate quantitation of the analytes it is preferable to detect  the bound
fraction rather than the unbound fraction, since only a small proportion of the
liposome population is likely to bind to the immobilized ligand. Besides, a
relatively larger change in the amount of bound analyte can be expected,
compared to the change in the free fraction, when analyte is present. Because it
is expected that also proteoliposomes without receptors are present, a
significant background signal will be codetermined in the free fraction.
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1.1 Methods in Biopharmaceutical Analysis
In order to qualitatively or quantitatively determine an analyte, several methods
are available in biopharmaceutical analysis. These methods include (a) direct
methods such as spectrophotometry or polarography, (b) separation methods
including high performance liquid chromatography (HPLC), gas
chromatography (GC), (capillary) electrophoresis and thin layer
chromatography (TLC) and (c) ligand binding assays like immunoassays and
receptor assays.
The discovery that pharmacologically active substances such as hormones,
neurotransmitters and drugs exert their action through specific receptor sites led
to the development of the receptor assay.
Receptor assays are unique amongst other methods used in bioanalysis, since
they do not only determine the concentration of the analyte, but are also
capable of measuring the affinity of the analyte to the specific receptor site.
Receptor assays utilize the first step (binding) in a cascade of physiological
events (Fig. 1.1).
                                                            
Part of this chapter appeared in:
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By definition, a receptor is a (macro) molecule which is able to recognize a
distinct chemical entity amongst many others, and which transduces the
information contained within that entity to the cell, resulting eventually in a
response such as activation of an enzyme (e.g. adenylyl cyclase), alteration of
membrane permeability etc. Most receptors are transmembrane glycoproteins
naturally occurring in cell membranes of different tissues and organs, although
there are also soluble receptors found in the cytoplasm and the nucleus of the cell
(e.g. receptors for steroids and thyroid hormones). In this chapter only  membrane
bound receptors will be described; however, the theory of receptor binding is also
valid for soluble receptors. (Membrane) receptors can be classified according to
pharmacological or structural characteristics.
Figure 1.1 Cascade of biological events that take place in a cell when a bioactive substance
binds to the binding site of a receptor. Receptor assays only make use of the first
(binding) step. L = bioactive compound (ligand); B = binding site (receptor); C =
coupling component (e.g. G-protein); E = effector (e.g. enzyme or ion channel).
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Pharmacologically, receptors are classified by their (relative) affinity and
selectivity of (1) antagonists (analytes with affinity for the receptor, but no
efficacy) and (2) agonists (analytes with both affinity and efficacy) as defined by
Kenakin et al. (1992). For receptor classification purposes, antagonists are
preferably used. Requirements are that measurements should be made under
equilibrium conditions and that the binding is competitive.
Structural (and functional) analysis distinguishes three main receptor groups:
(a) Receptors with a single transmembrane segment (e.g. the epidermal growth
factor receptor (EGFR) and the insulin receptor (IR)).
(b) Hetero-oligomeric receptors containing one or multiple binding sites and an
ion channel (e.g. the GABAA receptor, Fischer and Olsen 1986).
(c) Receptors interacting with GTP-binding proteins (G-proteins) usually
containing seven hydrophobic transmembrane segments; e.g. the
muscarinic acetylcholine receptor (mACR; Kerlavage et al., 1987) and the
β-adrenergic receptor (β-AR; Lefkowitz et al., 1983).
Many receptors are built from more than one subunit, for which multiple subtypes
can exist. For example, for the GABAA receptor, several subunits have been
discovered including α(1-6), β(1-4), γ(1-3), δ and ρ(1,2) subtypes (Levitan et al.,
1988 and Macdonald and Angelotti 1993). Various receptors have been cloned
and sequenced in recent years, as described for the muscarinic acetylcholine
receptor (Kubo et al., 1986), the epidermal growth factor receptor (Ullrich et al.,
1984) and the GABAA receptor (Macdonald and Angelotti 1993). Cloning of
receptors (or receptor subunits) followed by selective expression in carcinoma
cells or oocytes has given a better insight in the molecular basis of receptor
functionality and what subtypes might be needed for binding of analytes. This
may eventually lead to a more complete understanding of the basis of
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neurotransmitter and hormone action, the role of receptors in disease and health,
and might be advantageous in future drug development programs.
1.3 Ligand Binding Assays
1.3.1 The Immunoassay
In 1959, Yalow and Berson published their famous article about quantitation of
insulin in serum, using 125I-insulin and anti-insulin antibodies as binding proteins.
The basic idea behind this method was that there would be a competition between
a labeled antigen and an unlabeled antigen for the same (limited amount of)
antigen binding sites. Separation of the bound and free fractions made it possible
to determine the amount of labeled antigen in either one of the fractions. This
principle is still valid for the numerous variations made on the assay since then.
The interaction between a binding protein and a ligand is, in the case of an
immunoassay, a selective antigen-antibody interaction. In all types of
immunoassays, be it radio-immunoassays, fluorescence immunoassays or enzyme-
immunoassays, there is a distinction between competitive and non-competitive
methods. Detailed information on experimental set-ups and theoretical
backgrounds can be found in the excellent antibody manual by Harlow and Lane
(1988).
Competitive immunoassays
In this type of assay there is competition between a known amount of labeled
antigen and a sample (an unknown amount of unlabeled antigen) or standard, for a
limited concentration of antibodies. An increase in antigen in the sample will
lower the amount of labeled antigen that can bind to the antibodies. Many of
today’s immunoassays are heterogeneous; i.e. the free and bound antigen fractions
must be separated. Several separation methods are available, including
precipitation of the bound fraction with a secondary antibody and specific coating
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of a solid phase with the antigen or antibody, followed (after the incubation) by a
simple washing step to remove the unbound fraction. The amount of label in either
one of the fractions, for practical reasons this is usually the bound fraction, can be
determined, and is a measure for the concentration of antigen in the sample. As an
alternative, labeled antibodies can be used. A commonly used modification on the
procedure described above is the so-called 'sequential saturation' or titration
method, in which the (unknown) amount of antigen in the sample (or standard) is
bound to a known concentration of excess antibody. As a second step, the free
antibody binding sites will be occupied by labeled antigen.
Non-competitive immunoassays
Also several non-competitive immunoassays exist, e.g. direct or indirect two-site
(sandwich) immunoassays, and direct or indirect one-site immunoassays. In the
direct two-site assay, an excess amount of antibodies (Al1) bound to a solid phase
are incubated with standards or a sample, resulting in binding of the unknown
amount of antigen to the immobilized antibody. After washing, an excess of
labeled antibody (Al2
*) is added which will bind to the already fixed antigen. After
separation of bound and free fractions the activity in the bound fraction can be
determined. A disadvantage of this method is that it can only be used when the
antigen is large enough to accommodate two antibodies. The indirect method is
similar to the direct one, except that the secondary antibodies (Al2) are unlabeled.
Here, a third labeled antibody directed against immunoglobulins is added for
detection.
In the direct one-site immunoassay, the sample is incubated with an excess labeled
antibody (Al1
*) followed by incubation with an excess antigen immobilized on a
solid phase. In this case the non-bound antibodies will bind to the solid phase, and
binding will decrease with increasing amounts of antigen in the sample. The




1.3.2 The Receptor Assay
Principles of the receptor assay
The first example of a quantitative receptor assay was published by Lefkowitz et
al. (1970) describing the competition between ACTH and 125I-ACTH for specific
receptor sites in homogenates of adrenal cortical tissue. The same principles
originally used for immunoassays are applicable for receptor assays. In both
immunoassays and receptor assays the analyte [L] competes with a labeled ligand
[L*] for the same binding site on the protein [antibody [A] or receptor [R],
respectively] as shown for the receptor assay in equation (1).
[R] + [L] + [L*] ↔ [RL] + [RL*] (1)
Depending on the affinity of the analyte for its receptor, very high sensitivity can
be achieved. It is not uncommon that nanograms or even picograms of analyte can
be measured. Another feature of a receptor assay is the selectivity. Most receptors
bind a distinct class of structurally related molecules. This means that only the
total of (pharmacologically) active ligand and metabolites can be detected by the
assay when these molecules bind to the same site. This is also a limitation since no
discrimination can be made whether the detected molecule is the parent compound
or one of its active metabolites. Cross reactivity with structurally related but
pharmacologically inactive molecules (a major drawback in immunoassays) does
not occur. Also, when chiral substances are involved, only the active enantiomer
(eutomer) will bind to the receptor whereas the inactive distomer will not.
Radioreceptor assays have been described for a large number of receptor classes,
including benzodiazepine (Hunt et al., 1978, Lund 1981), muscarinic (Ensing et
al., 1984 and 1988), cholinergic (Covarrubias et al., 1986), alpha-adrenergic
(Greenberg et al., 1976), beta-adrenergic (Innis et al., 1978, Iwo et al., 1985),
opiate (Villiger et al., 1981) receptors as well as for human growth hormone
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(Ilondo et al., 1991), tricyclic anti-depressants (Innis et al., 1979) and neuroleptics
(Creese and Snyder 1977).
Receptor-ligand binding theory
The relationship between a fixed amount of receptor, labeled ligand (e.g.
radioligand) and the formed complex is shown in equation (2), where [R], [L*] and
[RL*] are the concentrations of receptor, labeled ligand and complex, respectively,
and k-1 and k1 are the dissociation and association rate constants, respectively:
[R] + [L*] ↔ [RL*] (2)
Since the amount of receptors is limited, saturation of the binding sites will occur
at high concentrations of labeled drug. Figure 1.2 shows a typical saturation curve
for benzodiazepine receptors by [3H]flunitrazepam. The total amount of binding
sites (Bmax) is found on the ordinate at the point where the curve reaches its
plateau. The amount of ligand that gives a 50% saturation of the receptor
represents the dissociation constant Kd.
Bmax and Kd can also be calculated using equation (3):
The dissociation constant Kd is inversely proportional to the affinity of the analyte
(or ligand) for the receptor and is defined by the ratio of the dissociation and
association rate constants:














Figure 1.2 Typical saturation curve for the membrane-bound benzodiazepine receptor using
[3H]flunitrazepam as the labeled ligand. Closed circles represent specific binding
and open circles the nonspecific binding. Binding parameters (Kd and Bmax) can be
calculated using the EBDA-LIGAND computer fitting program (Version 4.0;
Biosoft, Cambridge, UK), based upon a program originally developed by Munson
and Rodbard (1980), considering a one-site binding model.
Addition of a competitive (unlabeled) analyte will displace a certain amount of
labeled ligand, depending on the concentration of the former and on its
equilibrium binding constant Kd, resulting in two types of receptor complexes, as
described in equation (1). By varying the amount of analyte and keeping the
concentration of labeled ligand and receptor constant, calibration curves can be
constructed, as shown in figure 1.3. The IC50 value, i.e. the amount of analyte
displacing 50% of the bound labeled ligand can be determined from these curves.
Flunitrazepam free (nM)





















The affinity constant of the analyte (Ki) is related to the IC50 as described by the
Cheng-Prusoff equation (Cheng and Prusoff, 1973):
Figure 1.3 Hypothetical calibration curve of an analyte displacing a labeled ligand from its
receptor.
Sensitivity of receptor assays
The sensitivity of specific binding of a ligand to its receptor depends on the ratio
of concentration/Kd of the ligand being assayed.
An important parameter is the limit of detection (LOD), which can be defined as
the minimum concentration of analyte at which the fraction of bound labeled
ligand is significantly smaller than the fraction of bound labeled ligand in the
absence of analyte, and can be calculated using equation (6):
































 γ1 = a parameter from Student t-test which characterizes the error of the
determination of the concentration of labeled ligand in the absence of
analyte
 Kn
* = the constant for non-specific binding of the labeled ligand
 Kd
* = the dissociation constant of the labeled ligand
 [R]0 = the total receptor concentration
 [L*] = the concentration of the free labeled ligand
 Kd = the dissociation constant of the analyte
It can be seen from equation (6) that several factors determine the sensitivity of a
receptor assay.
(a) The LOD is directly proportional to the Kd of the analyte. In other words, when
the analyte has a high affinity (low Kd), less of it can be detected.
(b) Since the LOD is also directly proportional to the concentration of labeled
ligand, a minimum of the labeled ligand should be used to increase sensitivity.
A free concentration of labeled ligand equal or close to the dissociation
constant is considered to be a good compromise.
(c) The lower the amount of non-specific binding, the higher the sensitivity,
resulting in a decrease in the LOD.
Selectivity of receptor assays
During a receptor assay only pharmacologically active compounds will bind to its
receptor, while inactive compounds belonging to the same structural class or
compounds belonging to another structural class will not bind. Selectivity is
determined by the nature of the receptor preparation, the type of labeled ligand


























preparations containing a single receptor or a heterogeneous population of binding
sites can be used. If a heterogeneous receptor population is used, it is important to
choose the (labeled) ligand with care. If the labeled ligand and the analyte bind to
more than one class of receptors, depletion of both ligand and analyte might occur
when using heterogeneous receptors. For example, [3H]-spiperone is a potential
radioligand for D2 dopamine receptors, but is also labeling 5HT2 serotonin
receptors, α1-adrenergic receptors and the spirodecanone acceptor (Strange 1987).
Specific brain regions (e.g. corpus striatum) containing larger amounts of D2
receptors may be used to minimize the influence of binding to other receptors.
A more complicated situation occurs when a single receptor binds more than one
class of ligands. For example, the prolactin receptor is closely related to the
growth hormone receptor (Boutin et al., 1988) and will bind human prolactin and
human growth hormone with nearly equal affinity. However, the use of cultured
human lymphocytes containing specific growth hormone receptors (Lesniak et al.,
1974 and 1977) can circumvent this problem.
1.3.3 Methodology of the Receptor Assay
Receptor preparations
The receptor preparations needed for receptor assays are usually easily obtainable
from animal tissue, such as brain, liver or heart. Receptor density and the
pharmacological characteristics are among the most important factors in selecting
the most suitable receptor source. Besides the receptor of interest, other receptors
and non-receptor proteins will be found in the membranes, often causing
substantial non-specific binding. Receptor densities are typically in the range of
fmol-pmol per mg of total protein. A crude membrane homogenate prepared by
homogenizing animal tissue or organ in a 0.32 M sucrose solution will be
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satisfactory for most purposes. Differential centrifugation is required to obtain a
more purified subcellular fraction. Further purification is laborious and only
necessary when the receptor density is extremely low, or when the receptor
protein itself has to be characterized on a molecular level. A general approach for
the purification of receptors is to solubilize the membranes with an appropriate
detergent (see Section 1.4), followed by isolation of the receptor protein on e.g. an
affinity gel using immobilized ligand (T. Haga et al., 1990). A 100- to 1000-fold
purification may be achieved in this way. However, the method may also be
combined with other procedures, such as ion-exchange, hydroxyapetite or lectin
column chromatography. Aducci et al., (1993) has achieved a 5000-fold
purification of the fusicoccin receptor from maize using a combination of
adsorption, ion-exchange and gel-filtration chromatographies. On the other hand,
when trying to purify or solubilize membrane proteins, care must be taken to
prevent denaturation of the proteins.
As an alternative, recombinant receptors expressed by a single cell line may be
used. The advantage of using this type of receptor preparation is that identical
receptors can be produced in larger quantities. Besides, non-specific binding to
irrelevant proteins will be significantly reduced.
The choice of labeled ligand
Most labeled ligands used in the past three decades were radioligands. The main
advantage of using radioligands (mainly tritium) in receptor assays is that the
spatial structure of the ligand is not or only slightly modified by the incorporation
of an isotope. Therefore, the affinity of the labeled ligand can be expected to be
similar to the unlabeled compound. Besides, they are chemically stable and can be
sensitively detected over a wide range. However, there are several disadvantages
in using radiolabels as well, including high costs, radioactive waste, health
hazards, and the need of special equipment and licenses. For this reason
fluorescent labels for the use in receptor assays have been developed, as described
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for the α- and β-adrenergic and the opiate receptor by Corrêa et al., (1980), the
benzodiazepine receptor (Takeuchi and Rechnitz, 1991a, and Janssen, 1997) and
the estrogen receptor (Hwang et al., 1992). However, the attachment of a (bulky)
fluorescent moiety to a ligand often results in diminished affinity of the ligand to
its receptor. Moreover, since ligands are bound to distinct entities of the of the
receptor protein, many positions on the ligand are unsuitable for the attachment of
fluorescent labels.
Biotin labeled benzodiazepines have been used in an avidin-biotin binding assay
by Takeuchi et al., (1991b), and Hallowell and Rechnitz (1987) used
phenylcyclidine coupled with glucose-6-phosphate dehydrogenase in an enzyme-
amplified receptor assay for the acetylcholine receptor. A promising development
is the use of chemiluminescent labels. The latter have been used in a number of
immunoassays with similar or higher sensitivity than radioactive probes as
described by Weeks et al., (1983) and Stabler and Siegel (1990). Katoh et al.,
(1995) used acridinium labeled fibrinogen in a chemiluminescent receptor assay
for the exposed platelet fibrinogen receptor and found similar KI values as
compared with 125I-labeled fibrinogen.
Some general criteria, which apply to all labeled ligands used, are:
(a) They should bind to the same receptor site as the unlabeled ligands.
(b) They should be chemically stable and resistant to enzymatic and hydrolytic
degradation. The latter might be of particular concern when peptides are
used as labeled ligands.
(c) Non-specific binding to non-receptor sites and materials used must be
minimal.




Radioligands have to meet some additional criteria:
(e) They should be of high specific activity. This is necessary because the
receptor density in most tissues and organs is limited.
(f) They have to be radiochemically pure. Labeled impurities can contribute to
artifacts, such as curvilinear Scatchard plots, Hill coefficients smaller than
unity and poor specific to non-specific binding ratios.
Based on the discovery that many receptors can be subdivided into subtypes, it
should be clear that the labeled ligand and analyte should select the same receptor
subtype in order to obtain maximal specificity and sensitivity. Moreover,
differences in hydrophilic or lipophilic properties of ligands may also contribute to
heterogeneity in binding.
Separation of bound and free labeled ligand
During a receptor assay the labeled ligand and analyte are incubated under well-
controlled conditions. The incubation temperature and time are dependent on the
kinetics (association and dissociation rates of the ligand and analyte), but is
typically 30 to 60 minutes at 0°C to 37°C. In order to measure the amount of
labeled ligand bound to its receptor, separation of the bound and free fraction is
necessary. Separation methods include filtration through glass fiber filters or
centrifugation for membrane bound receptors, and dialysis, gel filtration,
precipitation of the receptor-ligand complex with PEG 6000-8000 or ammonium
sulfate followed by centrifugation or filtration, or adsorption of free ligand
followed by centrifugation when using soluble or solubilized receptors.
Centrifugation and filtration methods have the advantage that both bound and free
fraction can be collected and measured separately. Filtration, gel filtration and
ligand absorption assays are principally non-equilibrium techniques, causing
ligand dissociation, and are therefore not suitable for rapidly dissociating ligands.
Equilibrium dialysis and gel filtration have the disadvantage of being rather time
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consuming, which make them not practical when many samples have to be
analyzed.
1.4 Solubilization of Membrane Receptors
Solubilization of biological membranes by detergents eventually results in the
separation of the individual components (proteins and lipids) which the membrane
is built of, and is the necessary first step in the purification of membrane proteins.
Detergents are, like phospholipids, amphiphilic molecules, i.e. they have a
hydrophilic 'head' and a hydrophobic 'tail'. Many detergents are commercially
available, including non-ionic detergents such as the Tritons (e.g. Triton X-100
and Triton X-405), Nonidet P-40, Lubrol PX, octyl glucoside and octyl
thioglucoside and digitonin. A second class of detergents are the ionic detergents
of which the anionic detergents sodium cholate and sodium deoxycholate are the
most frequently used. Finally, zwitterionic detergents such as CHAPS and
CHAPSO may be used. The way a detergent solubilizes the membrane depends
highly on the type of detergent used as well as on the properties of the membrane.
Moreover, the absolute and relative concentrations of the detergent, phospholipid
and proteins present during the solubilization play a key role in the solubilizing
potency, i.e. final concentration of the detergent used.
Addition of a small amount of detergent to a membrane suspension (below the
critical micellar concentration, CMC, which is the concentration at which the
detergent molecules form micelles) will result in partitioning of the detergent
molecule between the aqueous phase and the membrane. Increasing the detergent
concentration will result in an increase in concentration in the bilayer, eventually
causing fragmentation of the membrane. When the detergent concentration
increases above the CMC, micelles will form, resulting in large-scale
solubilization of membrane proteins and lipids. Both mixed detergent-lipid-protein
micelles and detergent-lipid micelles can be found at this stage. A further increase
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in detergent concentration will mainly result in an increase of detergent micelles
and might also result in protein inactivation or even protein aggregation due to the
depletion of essential endogenous lipids.
Designing a solubilization procedure is mainly a case of trial and error, although
some rational considerations often can be made. For instance, the receptor-ion
channel complexes, e.g. the GABAA-benzodiazepine receptor, can be solubilized
effectively by ionic detergents such as sodium cholate or deoxycholate, although
also non-ionic and zwitterionic detergents have been used with some success.
Typically, different membrane proteins will become soluble at different detergent
concentrations, while some proteins, e.g. those membrane proteins attached to the
cytoskeleton, may not be solubilized at all.
1.5 Liposomes
Liposomes are spherical vesicles consisting of one or more lipid bilayers (usually
composed of phospholipids) surrounding an aqueous inner volume and are formed
spontaneously when lipid molecules are dispersed in aqueous media. Liposomes
are often used as a model membrane system, since they can be prepared in such a
way that they are similar to the native membrane bilayer. They were first
described by Bangham et al. (1965) who studied the nature of cell membranes.
Today, most interest into applications of liposomes is in the field of drug delivery
(Crommelin et al., 1997 and Siler-Marinkovic et al., 1997), gene therapy (Smith et
al., 1993) and liposomes are even produced by the cosmetic industry as
constituents of creams and lotions. As an analytical tool, liposomes have been
immobilized in gel beads for the chromatographical analysis of the specific
interactions between solutes and membrane proteins (Lundahl and Yang, 1991) or
drug partitioning in lipid bilayers (Beigi et al., 1995). Liposomes are also used in
immunoassays (Axelsson et al., 1981 and Litzinger and Huang, 1992) by cross-
linking antigens or antibodies to the liposome bilayer. Most types of
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immunoassays can be used in combination with liposomes. In some cases the
main difference is the replacement of the enzyme-substrate reaction used in the
'traditional' assay, by liposomes containing encapsulated marker molecules such as
fluorophores, chromophores or chemiluminescent molecules. Membrane proteins
can be purified and reconstituted in liposomes in order to study their structure and
function (see Chapter 3).
Structure of liposomes
The (most) commonly used structural components of liposomes are phospholipids
(Figure 1.4), of which the most common are phosphatidylcholines (lecithin).
Phosphatidylcholines are primarily used in liposomes because of their low cost
and neutral charge. Naturally occurring phosphatidylcholines (and other
phosphatidyl glycero-phospholipids) are mixtures of phospholipids with different
chain lengths and varying degrees of unsaturation. Other neutral phospholipids are
sphingomyelin and phosphatidylethanolamine. Negatively charged phospholipids
include phosphatidylglycerol, phosphatidic acid and phosphatidylserine.
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Figure 1.4 Some commonly occurring phosphatidyl glycero-phospholipids. PC and PE are
neutral since the positively charged nitrogen in the choline and ethanolamine
headgroups neutralizes the negative charge on the phosphate. All other
(phosphatidyl) glycero-phospholipids are negatively charged, as PA can even
have a double negative charge.
Cholesterol is another important constituent of biological membranes, since it
plays a key role in controlling the fluidity and permeability of the membrane.
Preparation of liposomes should be simple and reproducible, with sizes as
homogeneous as possible. Several types of liposomes can be distinguished,
ranging from small unilamellar vesicles (SUV) with diameters below 100 nm, to
large unilamellar vesicles (LUV) with sizes between 100 nm and 1000 nm.
Multilamellar vesicles (MLV) are comparable in size to LUVs and are generally
consisting of at least five concentric lamellae.
When size-exclusion chromatography (better known as gel filtration) is used as
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(100-200 nm on average) and mainly unilamellar. Since the method is simple and
fast, it is frequently used in reconstitution studies.
1.6 Concluding Remarks
Receptor assays offer the possibility to determine the pharmacological properties
of hormones, neurotransmitters and drugs. Moreover, receptor assays can be used
for selective and sensitive determination of these compounds in biological and
other relevant matrices. In this regard, it should be noted that receptor assays are
not mass detectors, but that their principle is based on affinity. Thus, very potent
substances (e.g. drugs) that are given in low dosages and are present in minute
amounts in the body, can often be analyzed properly with receptor assays. Also,
since the technique is simple and rapid it may be particularly useful to screen for
the presence of representatives from a certain pharmacological class (opiates,
benzodiazepines, neuroleptics, etc.), e.g. in clinical and forensic toxicology.
The labeled ligand, the receptor preparation and the incubation conditions have to
be chosen carefully in order to obtain a stable and, in most cases, near-
physiological medium. Association and dissociation rate constants of the ligand
and analyte determine the incubation time and the method needed to separate the
bound and free fractions. Limitations of receptor assays, caused mainly by the
type of biological materials used, can be reduced by using standardized receptor
preparations (e.g. purified or cloned receptors can lower the amount of non-
specific binding and hence increase the sensitivity of the assay) and by automation
of the procedure. The development of non-radioactive labeled ligands, and non-
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Solubilization of the Bovine
Brain Benzodiazepine Receptor
2.1 Introduction
To study the structure and function of membrane-bound receptors (and
membrane proteins in general) it is often necessary to solubilize the proteins, in
order to separate them from their lipid environment, followed by further
purification using e.g. affinity chromatographical techniques. Moreover,
solubilization of membrane proteins is also the first step in the reconstitution of
those proteins (see also Chapter 3).
When radioreceptor assays (RRA) are used to study the interaction of a ligand
(drug, hormone or neurotransmitter) with its receptor protein, the use of a crude
membrane homogenate as the receptor source is usually sufficient. Solubilized
receptors may be needed when non-radioactive receptor assays are used. For
example, in developing a fluorescent receptor assay (FRA) for the
benzodiazepine receptor, the presence of membrane-bound benzodiazepine
receptors caused a high background signal, due to scattering and
autofluorescence, which was minimized when a solubilized receptor
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chromatographic reconstitution of the bovine brain benzodiazepine receptor. Effects of lipid
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The major inhibitory neurotransmitter in the mammalian central nervous
system, γ-aminobutyric acid (GABA), interacts with central and peripheral
receptor subtypes. GABA induces membrane hyperpolarization by opening a
chloride channel in the GABAA receptor, which is part of a multireceptor
protein, also containing binding sites for psychoactive drugs such as the 1,4-
benzodiazepines, the barbiturates and for convulsant compounds like
picrotoxinin.
The large multireceptor protein (Mr ≈ 300 000) can be solubilized by a variety
of detergents, such as Triton X-100 (Lang et al., 1979), 1-O-n-octyl β-D-
glucopyranoside (β-octyl glucoside) (Hammond and Martin, 1986), sodium
cholate and sodium deoxycholate (Asano and Ogasawara, 1980 and Asano and
Ogasawara, 1981) and 3-[(3-cholamidopropyl)dimethylammonio]-1-propane
sulfonate (CHAPS) (Stephenson and Olsen, 1982). Though CHAPS appears to
be the only detergent capable of solubilizing the GABAA receptor with
retention of all types of binding sites (Hammond and Martin, 1986 and
Stephenson and Olsen, 1982), deoxycholate solubilizes larger amounts of
GABA and benzodiazepine sites than CHAPS (Hammond and Martin, 1986;
Asano and Ogasawara, 1980; Asano and Ogasawara, 1981 and Stephenson and
Olsen, 1982).
This chapter describes the solubilization of the benzodiazepine receptor with
deoxycholate. Saturation binding experiments were done to examine the
binding characteristics of the solubilized receptor preparation and were
compared to values found with membrane-bound receptors. The effect of
deoxycholate on the solubilized receptor binding assay was studied, as well as
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the effects of the pH of the incubation medium and the presence or absence of
KCl during the solubilization procedure.
2.2 Materials and Methods
Materials
Bovine serum albumin (type 5, 96-99%), bovine globulins (Cohn fractions II
and III), benzamidine hydrochloride (97%), bacitracin (50,000 units/g) and
sodium deoxycholate (>95%) were bought from Sigma (St. Louis, MO, USA).
[N-methyl-3H]flunitrazepam (82.0 Ci/mmol) was obtained from DuPont NEN
(Wilmington, DE, USA). Lorazepam was kindly provided by Wyeth
Laboratoria (Hoofddorp, The Netherlands). Other chemicals were of analytical
grade and were purchased from Merck (Darmstadt, Germany). Polyethylene
glycol (PEG) 6000 was supplied by Genfarma (Maarssen, The Netherlands),
polyethylene tubes by Greiner (Alphen a/d Rijn, The Netherlands), and glass
fiber filters (GF/B) by Whatman (Maidstone, UK). Rialuma scintillation
cocktail was obtained from Lumac (Olen, Belgium).
Preparation of membrane-bound receptors
Calf brains (minus the cerebellum), obtained from the slaughterhouse, were
stored at −80°C. The material was thawed and homogenized in 5 volumes (v/w)
of ice-cold 0.32 M sucrose using a glass-PTFE Potter-Elvehjem homogenizer
(R.W.18, Janke & Kunkel, Staufen i. Breisgau, Germany) at 1200 rpm. The
homogenate was centrifuged at 1000 g for 10 min at 4°C. The supernatant was
carefully decanted and centrifuged for 60 min at 100,000 g at 4°C. The pellet
was washed twice with 50 mM sodium phosphate buffer (pH 7.4) containing 1
mM EDTA followed by centrifugation for 30 min at 100,000 g at 4°C. The
final pellet was suspended in 5 volumes of the same buffer, rapidly frozen in
liquid nitrogen and lyophilized for 48 h. Lyophilized material could be stored at
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−20°C for at least 1 year with retention of receptor activity, which is in
agreement with the results of Lund (1981).
Solubilization of brain membranes
The lyophilized brain membranes were suspended to a protein concentration of
8mg/ml in ice-cold 50 mM Tris-HCl (pH range 6.7-8.2, 22°C) (buffer T)
supplemented with protease inhibitors (1 mM benzamidine HCl and 200 µg/ml
bacitracin), and 1 mM EDTA. The proteins were solubilized on ice by dropwise
addition of 20 mg/ml deoxycholate (pH 7.6), to a final detergent concentration
of 2 mg/ml. After 30 min, non-solubilized material was removed by
centrifugation at 100 000 g for 1 h at 4°C. To study the effect of KCl on the
solubilization efficiency, 0.0-1.0 M KCl was added to the 50 mM Tris-HCl
buffer (pH 7.6, 22°C) supplemented with protease inhibitors and EDTA as
described above.
The supernatant containing solubilized receptors was immediately used in the
binding assays and had a final protein concentration of approximately 5 mg/ml
when the proteins were solubilized at pH 7.6 with 0.5 M KCl added.
Binding assay
For the determination of the affinity of membrane-bound receptors for
flunitrazepam (FNM) and the number of binding sites, samples of the receptor
suspension containing 80 µg protein were incubated in polyethylene tubes for
45 min at 0-2°C with 20 µl aliquots of [3H]FNM stock solutions (in buffer T),
giving final concentrations ranging from 0.1 to 10 nM. The total volume of the
incubation mixture was adjusted to 200 µl with buffer T. To determine
nonspecific binding, the incubation was also done in the presence of an excess
of unlabeled ligand, 5 µM lorazepam. After the incubation, of 15 µl of a
solution of 33 mg/ml bovine globulins and 85µl of a 360 mg/ml PEG-6000
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solution were added to give a total of 100 µl PEG/globulins in buffer T. The
incubation was continued for another 12 min and then stopped by the addition
of 3 ml ice-cold buffer T. The mixture and two 3 ml rinsing portions of ice-cold
buffer T were filtered over Whatman GF/B filters, after which the filters were
transferred into scintillation counting vials, shaken in a 3.5 ml scintillation
cocktail for 2 h, and subjected to 5 min liquid scintillation counting (Packard
Tri-Carb 4000, Downers Grove, IL, USA). The binding assay for solubilized
receptors was done essentially as above, except that [3H]FNM concentrations
up to 20 nM were used.
The equilibrium dissociation constant (Kd) for the labeled ligand and the
maximal number of operative binding sites per mg protein (Bmax) were
calculated using the EBDA-LIGAND computer fitting program (Version 4.0;
Biosoft, Cambridge, UK), based upon the LIGAND program originally
developed by Munson and Rodbard (1980), considering a one-site binding
model.
Protein determination
The amount of protein in the receptor preparations was determined by a
modified Lowry method (Clark, 1984) after protein precipitation by the
addition of trichloroacetic acid to avoid interference of detergent and Tris
(Bensadoun and Weinstein, 1976). Bovine serum albumin was used as standard
and was treated as other samples.
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2.3 Results and Discussion
Deoxycholate is a suitable detergent for efficiently solubilizing GABA- and
benzodiazepine receptors from calf brain (Asano and Ogasawara, 1980 and
Asano and Ogasawara, 1981).
However, since deoxycholate concentrations higher than about 10 mg/ml
inhibit benzodiazepine receptor binding activity (Figure 2.1), solubilization was
done at the lowest concentration (2 mg/ml) still capable of solubilizing most of
the brain protein, to minimize the risk of irreversibly damaging the receptor
protein.
Figure 2.1 Influence of the concentration of sodium deoxycholate on the percentage
specific binding (Bx/Bo; where Bx is the specific binding (total binding − nonspecific
binding) at a certain deoxycholate concentration and Bo is the specific binding when no
detergent is present) of the solubilized GABAA-benzodiazepine receptor. The [
3H]FNM
concentration added to the receptor suspension was 1 nM. Bars represent the standard
deviation of measurement (n=5). During the incubation the pH of the mixture was 7.6 while
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The effect of the pH on the solubilization of the benzodiazepine receptor is
shown in Figure 2.2. The decrease in specific binding of [3H]flunitrazepam
([3H]FNM) to the benzodiazepine at higher pH values is probably not caused
by a lower solubilization efficiency of these binding sites, since the amount of
solubilized protein is in all cases around 60%, but may be due to (partly)
inactivation of the receptor binding sites. This pH effect was also described by
Ensing and de Zeeuw (1984) for the muscarinic acetylcholine receptor, where it
was shown that the equilibrium association constants (Ka) for pirenzepine were
decreasing at increasing pH, while for dexetimide the Ka values were decreased
when the pH was lower than pH 6.6 or higher than 7.8.
Figure 2.2 Effect of the pH on the solubilization of the benzodiazepine receptor,
measured as the amount of specific binding of 10 nM [3H]FNM. The values
are the averages of two experiments.
























The presence of KCl increased the amount of specific binding of [3H]FNM and
was reaching a plateau at 0.5 M (Figure 2.3). Yet, it did not increase the amount
of solubilized protein (~60%). It has been suggested that solubilization in the
presence of a high salt concentration (especially KCl) solubilizes a different
class of benzodiazepine receptors which are insensitive to solubilization
without salt (Lo et al., 1982).
Figure 2.3 Effect of KCl on the solubilization of the benzodiazepine receptor measured
as the amount of specific binding of 10 nM [3H]FNM. The values are the
averages of two experiments.
Optimal conditions for solubilization of the benzodiazepine receptor were
therefore determined to be 2 mg/ml deoxycholate in 50 mM Tris-HCl buffer
(pH 7.6) supplemented with protease inhibitors (1 mM benzamidine HCl and
200 µg/ml bacitracin) and 0.5 M KCl. This resulted in a protein recovery of
59±9% (n=6), while 54±6% [3H]FNM binding sites were recovered in the
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soluble fraction. Though it has been reported that more protein could be
solubilized using 5 mg/ml deoxycholate in combination with 150 mM KCl
protease inhibitors, the amount of active solubilized [3H]FNM binding sites did
not increase (Janssen.et al., 1996).
The solubilized receptor bound [3H]FNM with a Kd of 2.7±1.2 nM and a Bmax
of 0.40±0.04 pmol/mg protein (n=10), compared to a Kd of 1.46±0.17 nM and a
Bmax of 0.85±0.11 pmol/mg protein for membrane-bound receptors. Figure 2.4
shows representative saturation binding curves for the membrane-bound and
solubilized benzodiazepine receptors.
Solubilization of the GABAA-benzodiazepine receptor with 2 mg/ml sodium
deoxycholate in 50 mM Tris-HCl buffer (pH 7.6) supplemented with the
protease inhibitors, 1 mM EDTA and 0.5 M KCl did not greatly affect receptor
stability over a period of one day. However, the binding activity of the
solubilized benzodiazepine receptor was lost within a week when stored at
temperatures of −20°C or higher (results not shown), but was retained for at
least three months upon storage at −80°C (Janssen et al., 1997).
Chapter 2
42
Figure 2.4 Saturation curves of membrane-bound receptors () and solubilized receptors
(Ο). Open symbols represent specific binding and closed symbols the nonspecific binding.
2.4 Discussion
Solubilization of benzodiazepine receptors can result in a high-affinity soluble
receptor preparation as described in this Chapter, although more than 50% of
the receptor binding sites are lost or inactivated, which is in agreement with the
findings described by others (Hammond and Martin (1986), Asono and
Ogasawara (1980) and (1981), and Stephenson and Olsen (1982). Nevertheless,
solubilization is a necessary first step in the reconstitution of membrane
proteins (see Chapter 3). We selected deoxycholate at a low concentration (2
mg/ml) and addition of 0.5 M KCl, because these conditions preserved the
highest amount of active benzodiazepine receptor sites.





















F lu n it r a z e p a m  fr e e  (n M )
Solubilization of the Bovine Brain Benzodiazepine Receptor
43
References
Asano, T. and Ogasawara, N. (1980) Solubilization of the benzodiazepine
receptor from rat brain. Life Sci. 26, 607-613.
Asano, T. and Ogasawara, N. (1981) Soluble gamma-aminobutyric acid and
benzodiazepine receptors from rat cerebral cortex. Life Sci. 29, 193-200.
Bensadoun, A. and Weinstein, D. (1976) Assay of proteins in the presence of
interfering materials. Anal. Biochem. 70, 241-250.
Clark, S. (1984) Determination of membrane protein concentration. In: J.C.
Venter and L.C. Harrison (Eds.) Receptor Purification Procedures, Alan R.
Liss, New York, pp. 149-161.
Ensing, K. and de Zeeuw, R.A. (1984) Radioreceptor assay - a tool for the
bioanalysis of drugs. Trends Anal. Chem. 3, 102-106.
Hammond, J.R. and Martin, I.L. (1986) Solubilization of the benzodiazepine/γ-
aminobutyric acid receptor complex: comparison of the detergents
octylglucopyranoside and 3-[(3-cholamido-propyl)-dimethylammonio] 1-
propanesulfonate (CHAPS). J. Neurochem. 47, 1161-1171.
Janssen, M.J., Stegeman, M., Ensing, K. and de Zeeuw, R.A. (1996)
Solubilized benzodiazepine receptors for use in receptor assays. J. Pharm.
Biomed. Anal. 14, 989-996.
Janssen, M.J., Ensing, K. and de Zeeuw, R.A. (1997) Stability of solubilized
benzodiazepine receptors. Preparative Biochem. & Biotechnol.  27, 209-217.
Lang, B., Barnard, E.A., Chang, L.-R. and Dolly, J.O. (1979) Putative
benzodiazepine receptor: a protein solubilised from brain. FEBS Lett. 104,
149-153.
Lo, M.M.S., Strittmatter, S.M. and Snyder, S.H. (1982) Physical separation and
characterization of two types of benzodiazepine receptors. Proc. Natl. Acad.
Sci. USA 79, 680-684.
Lund, J. (1981) Radioreceptor assay for benzodiazepines in biological fluids




Munson, P.J. and Rodbard, D. (1980) Ligand: a versatile computerized
approach for characterization of ligand-binding systems. Anal. Biochem. 107,
220-239.
Stephenson, F.A. and Olsen, R.W. (1982) Solubilization by CHAPS detergent
of barbiturate-enhanced benzodiazepine-GABA receptor complex. J.
Neurochem. 39, 1579-1586.








Since the GABAA-benzodiazepine receptor (like many other membrane
proteins) is unstable in detergent solutions (see also Chapter 2), the (active)
receptor is preferably studied after reconstitution in lipid vesicles. Various
reports have appeared in recent years on the functional reconstitution of
receptor proteins, under which the benzodiazepine receptor (Schoch et al.,
1984, Sigel et al., 1985, Hirouchi et al., 1987 and Dunn et al., 1989), the δ
opiate receptor (Fujioka et al., 1988, Scheideler and Zukin, 1990 and Gomathi
and Sharma, 1993), the µ opiate receptor (Gioannini et al., 1993), the
myometrial oxytocin receptor (Klein and Fahrenholz, 1993) and the
acetylcholine receptor (Lindstrom et al., 1980 and Anholt et al., 1982). Dunn et
al. (1989) have reconstituted the β-octyl-glucoside-solubilized GABAA-
benzodiazepine receptor with size-exclusion chromatography (gel filtration) as
a tool for detergent depletion. Other methods included amongst others dialysis
of a mixture of Triton X-100- or CHAPS-solubilized benzodiazepine receptors
and lipids (Sigel et al., 1985) and adsorption of Triton X-100 (from a mixture
of Triton X-100-solubilized benzodiazepine receptors and soybean lipids) to
                                                            
Modified version of:
Viel, G.T., Yang, Q., Lundahl, P., Ensing, K. and de Zeeuw, R.A. (1997) Size-exclusion
chromatographic reconstitution of the bovine brain benzodiazepine receptor. Effects of lipid
environment on the binding characteristics. J. Chromatogr. A 776, 101-107. 
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Bio-Beads SM-2 (Schoch et al., 1984). In most cases, however, the
reconstituted receptors bound their radiolabeled ligands with lower affinities
(factor 2-6). The use of specific phospholipids during the reconstitution
procedure might improve the recovery of pharmacologically active receptors,
as described by Balen et al. (1994) for the D-1 dopamine receptor, where
phospholipid vesicles made of phosphatidylethanolamine (PE) and
phosphatidylcholine (PC) in a ratio PE:PC of 1:2 gave the highest recovery of
active receptor binding sites.
This chapter describes the reconstitution of sodium deoxycholate-solubilized
benzodiazepine receptors into vesicles of various lipid compositions. These
proteoliposomes were tested for flunitrazepam (FNM) affinity and binding
capacity, the effect of freezing and thawing on the FNM binding parameters,
and the long-term stability of the reconstituted receptor. The purpose was to
assess the efficiency of the chromatographic reconstitution procedure with a
variety of lipid mixtures. The proteoliposomes will be used as a tool in the
development of a non-radioactive receptor assay for benzodiazepines (see
Chapter 4-6).
3.2 Materials and Methods
Materials
Bovine serum albumin (type 5, 96-99%), bovine globulins (Cohn fractions II
and III), benzamidine hydrochloride (97%), bacitracin (50,000 units/g), bovine
brain lipids (type I (BPL), 50-60% phosphatidylserine), cholesteryl
hemisuccinate (free acid) and sodium deoxycholate (>95%) were obtained from
Sigma (St. Louis, MO, USA). Cholic acid (98% or >99%) was purchased from
Sigma or Fluka (Buchs, Switzerland), egg L-α-lecithin-phosphatidylcholine
(>95% PC) and soybean lipids (asolectin, i.e. crude soybean extract containing
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approx. 20% PC) were from Avanti Polar Lipids (Alabaster, AL, USA). [N-
methyl-3H]flunitrazepam (82.0 Ci/mmol) was obtained from DuPont NEN
(Wilmington, DE, USA). Lorazepam was kindly provided by Wyeth
Laboratoria (Hoofddorp, The Netherlands). Polyethylene glycol (PEG) 6000
was supplied by Genfarma (Maarssen, The Netherlands), Sephadex G-50
Medium by Pharmacia Biotech (Uppsala, Sweden), polyethylene tubes by
Greiner (Alphen a/d Rijn, The Netherlands), and glass fiber filters (GF/B) by
Whatman (Maidstone, UK). Rialuma scintillation cocktail was obtained from
Lumac (Olen, Belgium). Other chemicals were of analytical grade and were
purchased from Merck (Darmstadt, Germany).
Preparation of membrane-bound receptors
Calf brains (minus the cerebellum), obtained from the slaughterhouse, were
stored at −80°C. The material was thawed and homogenized in 5 volumes (v/w)
of ice-cold 0.32 M sucrose, using a glass-PTFE Potter-Elvehjem homogenizer
(R.W.18, Janke & Kunkel, Staufen i. Breisgau, Germany) at 1200 rpm. The
homogenate was centrifuged in a Beckman L8-55 Ultracentrifuge (Beckman
Instruments, Mijdrecht, The Netherlands) at 1000 g for 10 min at 4°C. The
supernatant was carefully decanted and centrifuged for 60 min at 100,000 g at
4°C. The pellet was washed twice with 50 mM sodium phosphate buffer (pH
7.4) containing 1 mM EDTA followed by centrifugation for 30 min at 100,000
g at 4°C. The final pellet was suspended in 5 volumes of the same buffer,
rapidly frozen in liquid nitrogen and lyophilized (Hetosicc CD 52-1, Heto,
Birkerød, Denmark) for 48 h. Lyophilized material could be stored at −20°C
for at least 1 year with retention of receptor activity, which is in agreement with
the results of Lund (1981).
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Solubilization of brain membranes
The lyophilized brain membranes were suspended to a protein concentration of
8mg/ml in ice-cold 50 mM Tris-HCl (pH 7.4, 22°C) (buffer T) supplemented
with protease inhibitors (1 mM benzamidine HCl and 200 µg/ml bacitracin),
0.5 M KCl and 1 mM EDTA. The proteins were solubilized on ice by dropwise
addition of 20 mg/ml deoxycholate (pH 7.6), to a final detergent concentration
of 2 mg/ml. After 30 min, non-solubilized material was removed by
centrifugation at 100 000 g for 1 h at 4°C.
The supernatant containing solubilized receptors was directly used in the
reconstitution procedures and had a protein concentration of approximately 5
mg/ml.
Reconstitution of the solubilized receptor by size-exclusion
chromatographic detergent depletion
The procedure followed for the reconstitution of membrane proteins was
essentially as described for liposome preparation by Brunner et al. (1976), for
proteoliposome preparation by Lundahl and Yang (1991) and as applied to the
human red cell glucose transporter by Brekkan et al. (1996a). Briefly, lipid
mixtures of the compositions specified in the Results section were dissolved in
chloroform and subjected to rotary evaporation in a round-bottomed flask.
Redissolution and evaporation was repeated twice with diethylether and the
lipid film was flushed with nitrogen. The lipids were dispersed with 125 mM
sodium cholate in 50 mM Tris-HCl (pH 8.0, 22°C) to obtain a lipid
concentration of 75 mg/ml (approximately 100 mM). A 1.5 ml aliquot of this
solution was mixed with 2.5 ml of deoxycholate-solubilized membranes and
applied with a flow of 1.5 ml/min to a 39 cm × 2 cm Sephadex G-50 M gel
bed in buffer T supplemented with 0.1 M KCl at 4°C. The void volume
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fractions containing the proteoliposomes were collected and pooled, and the
amounts of protein and phosphorus were determined as described below.
To study the effect of freezing and thawing of the proteoliposomes on the
receptor, the tube containing the proteoliposome suspension obtained after the
Sephadex chromatography was immersed for 5 min in a CO2(s)-ethanol bath
(approx. −70°C) and then for 5 min in a water bath at 25°C. The suspension
was vigorously mixed by vortex and the freeze-thawing cycle was repeated
once. Proteoliposomes and freeze/thawed proteoliposomes were used
immediately in the binding experiments. Alternatively, (freeze/thawed)
proteoliposomes can be stored at −20°C for at least 2 months without loss of
receptor binding (see Results section). The size distribution of the formed
proteoliposomes was determined with dynamic laser light scattering using a
particle sizing system (Model 370, Nicomp, Santa Barbara, CA, USA)
Binding assay
For the determination of the affinity of reconstituted receptors for
flunitrazepam (FNM) and the number of binding sites, samples of the receptor
suspension containing 80 µg protein were incubated in polyethylene tubes for
45 min at 0-2°C with 20 µl aliquots of [3H]FNM stock solutions (in buffer T),
giving final concentrations ranging from 0.1 to 10 nM. The total volume of the
incubation mixture was adjusted to 200 µl with buffer T. To determine
nonspecific binding of [3H]FNM, the receptor was also incubated with an
excess of unlabeled ligand (5 µM lorazepam). After the incubation, 15 µl of a
solution of 33 mg/ml bovine globulins and 85µl of a 360 mg/ml PEG-6000
solution were added (to give a total of 100 µl PEG/globulins in buffer T). The
incubation was continued for another 12 min and then stopped by the addition
of 3 ml ice-cold buffer T. The mixture and two 3 ml rinsing portions of ice-cold
buffer T were subsequently filtered over Whatman GF/B filters, after which the
filters were transferred into scintillation counting vials, shaken in 3.5 ml
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scintillation cocktail for 2 h, and subjected to 5 min liquid scintillation counting
(Packard Tri-Carb 4000, Downers Grove, IL, USA). The binding assay for
solubilized receptors was done essentially as above, except that [3H]FNM
concentrations up to 20 nM were used. The equilibrium dissociation constant
(Kd) for the labeled ligand and the maximal number of functional binding sites
per mg protein (Bmax) were calculated using the EBDA-LIGAND computer
fitting program (Version 4.0; Biosoft, Cambridge, UK), based upon the
LIGAND program originally developed by Munson and Rodbard (1980),
considering a one-site binding model.
Protein and phosphorus determinations
The amount of protein in the receptor preparations was determined by a
modified Lowry method (Clark, 1984) after protein precipitation by the
addition of trichloroacetic acid to eliminate interference of detergent and Tris
(Bensadoun and Weinstein, 1976). Bovine serum albumin was used as standard
and was treated as the other samples. Phospholipids were determined as
phosphorus as described by Bartlett (1959).
 3.3 Results and Discussion
Reconstitution of solubilized benzodiazepine receptors and FNM affinity
to the benzodiazepine receptor
The deoxycholate-solubilized benzodiazepine receptor (approx. 5 mg
protein/ml and 20-40 mM phospholipids) was reconstituted by size-exclusion
chromatography on Sephadex G-50 M, in the presence of endogenous bovine
brain lipids and additions of soybean lipids (Aso), brain phospholipids (BPL),
cholesteryl hemisuccinate (Cholh) and egg phosphatidylcholine (EPC) in
various combinations (Table 3.1). Only slight differences in reconstitution
efficiency were seen when other lipid combinations were used. The
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concentration of KCl in the eluent affected the reconstitution efficiency: with
0.1 M KCl, 52±7% of the total solubilized proteins were incorporated into
proteoliposomes composed of 100 mM EPC (and endogenous brain lipids),
while only 30-40% of the proteins were incorporated in the presence of 0.5 M
KCl. The phospholipid concentration was between 11 and 17 mM in all
preparations tested.
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Table 3.1
Reconstitution of the benzodiazepine receptor using 0.1 M KCl in the eluent and the
effect of freezing and thawing on the binding properties of the reconstituted receptor
Lipids addeda Specific [3H]FNM Specific [3H]FNM
bindingb bindingb after freeze-
thawing
Bmax     Kd (nM) Bmax            Kd
(nM)
(pmol/mg protein) (pmol/mg protein)
Aso 0.25  2.9 0.42
2.8
Aso/BPL/Cholh (7:3:1) 0.16 2.1 0.26
2.6
EPC/Aso/BPL (3.5:3.5:3) 0.12 2.4 0.20
2.7
EPC (100 mM) 0.09 4.0 N.D.c
N.D.c
EPC/BPL/Cholh (7:3:1) 0.07 2.0 0.20
3.8
Aso/BPL (7:3) 0.04 2.2 0.25
3.2
EPC/Aso/BPL/Cholh (3.5:3.5:3:1) 0.04 1.4 N.D.c
N.D.c
Membrane homogenated 0.85±0.11 1.5±0.2 N.D.c
N.D.c
Solubilized receptorsd 0.40±0.04 2.7±1.2 N.D.c
N.D.c
a Lipids added in the reconstitution experiments. The ratio (w/w) of the lipids is shown in
parentheses. The total lipid concentration was approximately 100 mM. Aso = asolectin
(soybean lipids); BPL = brain phospholipids; EPC = egg phosphatidylcholine; Cholh =
cholesteryl hemisuccinate.
b The values are the averages of 2-4 reconstitution experiments. The average relative SEM
was ±40% for the Bmax values and ±13% for the Kd values.
c N.D.; not determined.
d  Values for comparative purposes
Saturation binding experiments were done to examine the [3H]FNM binding
characteristics of the proteoliposomes. Although the lipid composition of the
liposomes was changed and various lipid sources were used, the Kd values were
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not dramatically affected, but were similar to those obtained with the
solubilized receptor (Table 3.1). Larger variations were found in the Bmax
values, which fell between 0.04 and 0.25 pmol/mg protein (10-63% of the Bmax
value found with the solubilized receptor).
For a given preparation of solubilized material the differences in Bmax after
reconstitution were small, in contrast to the variation seen when the receptors
originated from different solubilizates (results not shown).
When the benzodiazepine receptor was reconstituted with the co-solubilized
endogenous brain membrane lipids only, the binding was almost completely
lost, although still 60% of the total protein was incorporated in the formed
liposomes. Considering the good Kd value and the higher amount of binding
sites (Bmax) found when the benzodiazepine receptor was reconstituted in
asolectin proteoliposomes, we selected asolectin as the lipid source in further
reconstitution experiments.
Effect of freeze/thawing of proteoliposomes on the [3H]FNM binding to
reconstituted benzodiazepine receptor
During freeze/thawing, (proteo)liposomes fuse to form larger
(proteo)liposomes, as indicated by increasing inner volumes (Pick, 1981;
MacDonald and MacDonald, 1993 and Brekkan et al., 1996b). This may
provide a more favorable environment for a large multireceptor complex such
as the GABAA-benzodiazepine receptor. The proteoliposomes were therefore
freeze-thawed, which resulted in increasing Bmax values, whereas the changes
Kd values were relatively small (Table 3.1).
The highest Bmax value obtained was 0.42±0.17 pmol/mg protein for
proteoliposomes prepared with soybean lipids (asolectin), which is similar to
the Bmax found with solubilized receptor.
The Bmax values doubled on the average although the variations between
repetitive experiments were large.
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The size distribution of the proteoliposomes was determined by dynamic laser
light scattering. Figure 3.1A shows the size distribution of asolectin made
proteoliposomes. The mean diameter of the vesicles was determined to be 75
nm. 99% of all vesicles were smaller than 290 nm. Proteoliposomes made from
other lipid combinations showed roughly the same size distribution. A more
homogeneously sized liposome population might be formed when the formed
proteoliposomes would be extruded through membrane filters (Turánek, 1994).
Figure 3.1 Analysis of the vesicle size of asolectin-made proteoliposomes as determined
by dynamic laser light scattering. A: vesicle size distribution of freshly
prepared proteoliposomes and B: vesicle size distribution of the
proteoliposomes after a freezing and thawing cycle. The proteoliposomes
contained approx. 100 mM asolectin.
The size distribution of the asolectin proteoliposomes after freezing and
thawing is shown in Figure 3.1B, where the mean size of proteoliposomes
made with asolectin was determined to be 150 nm, which is twice the size of
Vesicle size (nm)






































the originally prepared proteoliposomes. 99% of the proteoliposomes were
smaller than 550 nm. For proteoliposomes made with other lipid combinations,
the increase of size was smaller (1.2-1.5 times increase). The larger size of the
vesicles after freezing and thawing might be the cause of the increase in Bmax
since a high curvature of the membranes of the original vesicles may give
(partial) inactivation of the receptor protein. However, the higher Bmax values
seen with proteoliposomes made with lipids other than asolectin cannot just be
explained by the (smaller) increase in size of the vesicles. Therefore, other
(unknown) factors than particle size seem to plat a role in this phenomenon.
Stability of the reconstituted benzodiazepine receptor
Whereas lyophilized membrane-bound benzodiazepine receptors can be stored
for at least one year at −20°C with retention of the binding characteristics,
solubilized receptors are more susceptible to inactivation of the receptor
binding due to the presence of detergents, although Janssen (1997) described
that solubilized receptors retained their high binding capacity for at least 2
months when stored at −80°C.
It was anticipated that the stability of the receptor would be increased after
reconstitution. We examined the stability of the reconstituted receptor over a 2
month period under a variety of storage conditions. At 4°C, about 20% of the
binding capacity of the reconstituted benzodiazepine receptor was retained after
2 weeks (Figure 3.2).
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Figure 3.2 Long-term stability of reconstituted GABAA-benzodiazepine receptors stored
at 4°C (•), −20°C (◊) or −80°C (s).  Bt is the specific binding at day t, B0 is the specific
binding at day 0 (freshly prepared proteoliposomes). The [3H]FNM concentration added to the
proteoliposome suspension containing the benzodiazepine receptor was 1 nM. The receptors
were reconstituted using egg phosphatidylcholine-asolectin-brain phospholipids (3.5:3.5:3),
and the proteoliposomes were formed during gel filtration on Sephadex G-50 M in buffer T
supplemented with 0.1 M KCl.
At −20°C, −80°C, the binding capacity was essentially retained during a period
of 2 months. The increase in the Bmax value observed when the proteoliposomes
were stored at −80°C was probably the result of proteoliposome fusion upon
freezing and thawing, as described above. Alternatively, proteoliposomes could
be lyophilized and stored at −20°C for a 2 month period without loss of the
binding parameters (result not shown).
























Reconstitution of membrane proteins into liposomes offers the possibility to
study these proteins in a stable environment, similar to that in the native
membrane. Although the amount and type of lipids present in the bilayer are
important to the activity of the (receptor) protein, it is difficult to predict the
optimal lipid composition in the proteoliposomes. Hammond and Martin
(1987) showed that the addition of phosphatidylserine at concentrations as low
as 5 µM during and after the solubilization of the benzodiazepine receptor from
synaptic membranes, enhanced flunitrazepam binding. According to Moynagh
and Williams (1992), both phosphatidylserine and phosphatidylinositol were
effective in preserving and even stimulating the (peripheral) benzodiazepine
receptor activity. The use of mild solubilization conditions may preserve
various endogenous and probably critical phospholipids. The other lipids added
during the reconstitution experiments showed no dramatic differences in the
binding characteristics of the benzodiazepine receptor, although the best results
were obtained with asolectin, a crude lipid containing soybean extract. In
contrast to Hammond and Martin (1987) and Moynagh and Williams (1992),
addition of extra phosphatidylserine (a major constituent in type I brain
phospholipids) did not increase the number of operative benzodiazepine
binding sites.
Since the GABAA-benzodiazepine receptor complex is large (about 300 kDa),
receptor activity may be reduced in smaller-size vesicles. The results after
freezing and thawing which gave larger-size vesicles resulted in more binding
sites, although particle size may not be the only factor involved in this
phenomenon. Alternatively, freezing and thawing could reorganize the
membrane and facilitate better incorporation of the receptor complex in the
bilayer.
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In this study, our goal was to obtain the active benzodiazepine receptor
reconstituted in lipid vesicles. Although the amount of binding sites (Bmax) of
the benzodiazepine receptor found after reconstitution in asolectin liposomes is
considerably lower than that found in crude membrane homogenate, which is
caused by losses of protein and/or receptor activity during solubilization and, to
a less extent reconstitution (also found by other investigators), the Kd values
obtained were lower (thus a higher affinity) than described by others (Dunn et
al. 1989, Sigel et al. 1985, and Schoch et al. 1984). Therefore, we were able to
successfully reconstitute the benzodiazepine receptor in a stable form, with
preservation of high affinity binding sites. The proteoliposomes could be an
essential element, as a carrier for the benzodiazepine receptor and
nonradioactively labeled entities, in the development of a heterogeneous
nonradioactive receptor assay (see Chapters 4-6).
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Receptor assays traditionally make use of radioligands for the detection of the
binding of these ligands or analytes. Recently, other types of labels for receptor
assays have been developed such as fluorescent labels (reviewed by Baindur
and Triggle, 1994a and 1994b), biotin labeled ligands (Chen et al., 1992, and
Takeuchi et al.,1992) and enzymes (Santos and Rechnitz, 1990 and Hallowell
and Rechnitz, 1987). The main problem of using these labels lies in the fact
that in almost all cases the binding characteristics of the labeled ligand were
significantly reduced in comparison with the parent compound (precursor).
Janssen (1997) described the affinities of fluorescent-labeled 1,4-
benzodiazepines, fluorescent-labeled 1,2-annelated 1,4-benzodiazepines and
their precursors, for the benzodiazepine receptor (Table 4.1).
Figure 4.1 Basic structures of 1,4 benzodiazepines and 1,2 annelated benzodiazepines.
For benzodiazepines, only labeling at position 1 did not much influence the




























1,2-annelated 1,4-benzodiazepines). High affinities could be obtained by using
a small fluorophore and a spacer to optimize the distance between the
fluorophore and the drug. A further requirement for a suitable fluorescent
ligand is that if hydrolysis occurs, the resulting products should have no affinity
for the receptor binding sites.
To circumvent these difficulties, we tried to construct a different fluorescent
receptor assay, where the ligand is immobilized to a solid support (see Chapters
5 and 6 for details) and the receptor is (indirectly) labeled by reconstitution in a
liposome containing fluorescent lipids. Since the constituents of a membrane
(and of proteoliposomes) may have some autofluorescence in the ultraviolet
and lower visible range (250-400 nm), the fluorescent lipid probes should have
an excitation (and emission) wavelength that should be as high as possible,
preferably exceeding 450 nm. Of these, fluorescein (λex=492), rhodamine B
(λex=550 nm) and Bodipy FL (λex=505 nm) fulfill this requirement (see Figure
4.2 for the structures of some commonly used fluorophores).
A second requirement is that the fluorophore must have high fluorescence
intensity in an aqueous environment, since the receptor assay is (normally)
done in such a medium. However, when the receptor-bound fraction is
measured, organic solvents may also be used, with or without prior dissociation
of the bound fraction (Janssen, 1997). The use of organic media also might
improve the fluorescence characteristics of the probes.
Furthermore, the detection limit of the fluorescent lipid probe is dependent on the
instrumentation used. Chromatographic fluorescence detectors are known to usually be
more sensitive than static detectors (Janssen, 1997).
In this chapter we investigate which (commercially available) fluorescent lipids may be
suitable for use as a label in fluorescent liposomes. We therefore selected three
fluorescent labels (Figure 4.3 and Table 4.2): N-(5-dimethylamino-naphthalene-1-
sulfonyl)-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine, triethylammonium
salt (dansyl DHPE), N-(5-fluoresceinthiocarbamoyl)-1,2-dihexa-decanoyl-sn-glycero-
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3-phosphoethanolamine, triethyl-ammonium salt (fluorescein DHPE) and 2-(4,4-
difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-pentanoyl)-1-hexa-decanoyl-sn-
glycero-3-phosphocholine (β-Bodipy Fl C5HPC).
Table 4.1 KI-values of fluorescent-labeled 1,4 benzodiazepines, fluorescent-labeled 1,2-
annelated 1,4 benzodiazepines and their precursors (from Janssen, 1997).
Precursors and fluorescent derivatives     Ki
Oxazepam 16.7 nM
Mmc-O-CO-(CH2) 2-CO-oxazepam   >1 mM
Lormetazepam   1.2 nM
Mmc-O-CO-(CH2) 2-CO-lormetazepam  114 nM
Nitrazepam   7.4 nM
7-aminonitrazepam (Ro5-3072)  470 nM
Dansyl-Ro5-3072   >1 mM
Flurazepam 10.4 nM
Didesethylflurazepam (Ro7-1986)   4.9 nM
Dansyl-Ro7-1986  167 nM
Bodipy-Ro7-1986    67 nM
NBD-(CH2) 2-CO-Ro7-1986 (Velazquez et al., 1989)    51 nM
NBD-(CH2) 5-CO-Ro7-1986 (Velazquez et al., 1989)  132 nM
Fluorescein-Ro7-1986 (McCabe et al., 1990)  163 nM
AMCA-Ro7-1986 (Takeuchi and Rechnitz, 1991)   8.6 nM
Flumazenil   0.6 nM
Desethylflumazenil (Ro15-3890)   >1 mM
Mmc-Ro15-3890  121 nM
Mmc-O-CO-(CH2) 3-Ro15-3890   6.5 nM
Fluorescein-NH-(CH2) 3-Ro15-3890 (McCabe et al., 1990)    63 nM
NBD-NH-(CH2) 3-Ro15-3890 (Havunjian et al., 1990)   5.7 nM
1021-S (Taguchi and Kuriyama, 1984)   0.4 nM
NBD-1021-S (Velazquez et al., 1989)    85 nM
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Fluorescein: λex = 492 nm Rhodamine B: λex = 550 nm
λem = 520 nm λem = 585 nm
Dansylchloride: λex = 340 nm Bodipy Fl-3-propionic acid: λex = 505 nm
λem = 480-520 nm    λem = 511 nm
F-NBD: λex = 470 nm BrMmc: λex = 315 nm
λem = 530 nm λem = 400 nm
Figure 4.2 Structures of some commonly used fluorophores.
Dansyl DHPE and fluorescein DHPE are phosphatidylethanolamine with
fluorescent-labeled headgroups, whereas Bodipy FL C5HPC is a
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Figure 4.3 Structures of the used fluorescent-labeled lipids.
(Proteo)liposomes containing fluorescent lipids might increase the sensitivity
of the receptor assay, since more than one fluorescent lipid may participate in a
single receptor-ligand binding interaction. We therefore determined the amount
of labeled lipids that can be accommodated by the liposome without quenching
effects. Moreover, since only a small fraction of the liposomes will bind to the
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were recorded from the fluorescent lipids and from the fluorescent lipids
incorporated in liposomes.
Table 4.2 Data table containing molecular weights (MW), absorption (ABS) and
emission (EM) wavelengths and the extinction coefficient (ε ×10-3) for the
three used fluorescent phospholipids. * : values for ε are approximate. All
lipids are freely soluble in ethanol and chloroform (data from the Molecular
Probes Inc. catalog, Eugene, OR, USA).
Lipid MW         ABS (nm)          EM (nm)           {ε x 10-3}*
            (λex)             (λem)
  Dansyl DHPE 1026 336 517      4.5
  Fluorescein DHPE 1183 496 519    88
  Bodipy FL C5HPC  798 503 512    80
The most suitable fluorescent-labeled phospholipid was selected by comparing
the fluorescent characteristics and was used in the fluorescent receptor assay
(Chapter 6).
4.2 Materials and Methods
Materials
Cholic acid (98%) was obtained from Sigma (St. Louis, MO, USA). Soybean
lipids (asolectin, i.e. crude soybean extract containing approx. 20%
phosphatidyl-choline) were from Avanti Polar Lipids (Alabaster, AL, USA). N-
(5-dimethyl-aminonaphthalene-1-sulfonyl)-1,2-dihexadecanoyl-sn-glycero-3-
phosphoethanol-amine, triethylammonium salt (dansyl DHPE), N-(5-
fluorescein-thiocarbamoyl)-1,2-dihexa-decanoyl-sn-glycero-3-
phosphoethanolamine, triethyl-ammonium salt (fluorescein DHPE) and 2-(4,4-
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difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-pentanoyl)-1-hexa-
decanoyl-sn-glycero-3-phosphocholine ( β-Bodipy Fl C5HPC) were obtained
from Molecular Probes, Inc. (Eugene, OR, USA). Sephadex G-50 Medium
was from Pharmacia Biotech (Uppsala, Sweden) and polyethylene tubes were
obtained from Greiner (Alphen a/d Rijn, The Netherlands). Other chemicals
were of analytical grade and were purchased from Merck (Darmstadt,
Germany).
Preparation of (fluorescent-labeled) liposomes
The procedure followed for the preparation of (labeled) liposomes was
essentially as described for liposome preparation by Brunner et al. (1976), for
proteoliposome preparation by Lundahl and Yang (1991) and as applied to the
human red cell glucose transporter by Brekkan et al. (1996). Briefly, 150 mg
asolectin with or without fluorescent-labeled phospholipids (amount specified
in the Results and Discussion section) were dissolved in approximately 20 ml
chloroform and subjected to rotary evaporation in a round-bottomed flask.
Redissolution and evaporation was repeated twice with diethylether and the
lipid film was flushed with nitrogen. The lipids were dispersed in 2 ml 125 mM
sodium cholate in 50 mM Tris-HCl (pH 8.0, 22°C) to obtain a lipid
concentration of 75 mg/ml (approximately 100 mM). 1.5 ml of this lipid
solution was applied with a flow of 1.5 ml/min to a 39 cm × 2 cm Sephadex
G-50 M gel bed in 50 mM Tris-HCl (pH 7.4, 22°C) supplemented with 0.1 M
KCl at 4°C. The void volume fractions containing the proteoliposomes were
collected and pooled (approx. 15 ml total volume) and used immediately in the
experiments. Phospholipids were determined as phosphorus as described by
Bartlett (1959) and were 13-17 mM.
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Solubilization and reconstitution of the benzodiazepine receptor
Solubilization of the benzodiazepine receptor and reconstitution of the receptor
in asolectin proteoliposomes was done as described in Chapters 2 and 3.
Determination of the fluorescence characteristics of the fluorescent-labeled
liposomes
Fluorescence emission spectra of 10-fold diluted fluorescent-labeled liposomes
(dilution in 50 mM Tris-HCl buffer; pH 7.4) and fluorescence intensities of
undiluted fluorescent-labeled liposomes were recorded on a Kontron SFM 25
spectrofluorometer (Zürich, Switzerland).
4.3  Results and Discussion
The amounts of fluorescent lipids incorporated in asolectin liposomes varied
between 5 and 1000 µg per 150 mg total lipids (weight ratio range 1/30000-
1/150) for fluorescein DHPE and dansyl DHPE, and between 1 and 50 µg per
150 mg total lipids (weight ratio range 1/150000-1/3000) for Bodipy FL
C5HPC. Because of the high costs of Bodipy-labeled lipids, a lower
concentration of this particular lipid was used. In Figure 4.4 the fluorescence
intensities of the different fluorescent liposome preparations are depicted.
Both dansyl DHPE and fluorescein DHPE showed quenching at higher
concentrations of fluorescent-labeled lipids added. Due to the lower fluorescent
lipid-concentration range of the Bodipy-containing liposomes, no quenching
was observed in this preparation at these concentrations. The optimum
excitation and emission wavelengths of the three fluorescent liposome
preparations in 50 mM Tris-HCl buffer (pH 7.4) are reported in Table 4.3.
The fluorescence excitation- and emission spectrum of dansyl DHPE
incorporated in liposomes showed a broad peak in the range of 300-650 nm,
rather than a single sharp peak, which makes this probe less suitable. Since the
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excitation wavelength of dansyl DHPE is 336 nm, interference of the matrix
(lipids and/or proteins) can be expected at this wavelength, which ultimately
could lead to increased background signals caused by autofluorescence.
Figure 4.4 Measured fluorescence intensities (arbitrary units) of asolectin
proteoliposomes containing fluorescein DHPE (A), Bodipy FL C5HPC  (B)
and dansyl DHPE (C).
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Table 4.3 Fluorescence characteristics of the fluorescent labeled liposomes compared to
the fluorescence characteristics of the fluorescent lipids.
λex (nm) λem (nm)
Dansyl DHPE    336 517
Dansyl DHPE liposomes    350    509
Fluorescein DHPE    496    519
Fluorescein DHPE liposomes    498    523
Bodipy FL C5HPC    503    512
Bodipy FL C5HPC liposomes    507    513
For the remaining two probes the amount of autofluorescence caused by
membrane proteins and lipids was investigated. Membrane proteins containing
the benzodiazepine receptor were solubilized with 0.2% deoxycholic acid
(from a calf brain homogenate) (see Chapter 2 for details about the
solubilization procedure), and were reconstituted in asolectin liposomes with
and without fluorescent lipids (250 µg fluorescein DHPE and 50 µg Bodipy FL
C5HPC per 150 mg asolectin, respectively). In both cases the amount of
autofluorescence caused by the matrix was less than 5% (results not shown).
In order to use the fluorescently labeled (proteo)liposomes in a receptor assay,
it is important that low amounts of fluorescent (proteo)liposomes can be
detected. We therefore determined the lowest amount of fluorescent liposomes
that could still be detected. In the case of fluorescein DHPE-asolectin
liposomes (250 µg fluorescein DHPE per 150 mg total lipids), the preparation
could be diluted 100,000 fold, while having a fluorescence intensity
significantly above background levels. With Bodipy FL C5HPC-asolectin
liposomes (50 µg Bodipy FL C5HPC per 150 mg total lipids) a 10,000 times
dilution could still be detected. It should be noted that only liposomes
containing receptors will be detected. Theoretical estimations, based on a
number of assumptions, indicate that (far) less than 10% of the liposomes
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contain a receptor. The latter implies that the maximal dilution of
proteoliposomes that can be used in the receptor assay is limited by this factor.
Therefore, fluorescein-DHPE lipids were selected for use in the fluorescent
receptor assay, because a high degree of labeling of the liposomes could be
achieved without quenching; in other words, small amounts of liposomes can
be detected in the assay. Although the fluorescent characteristics of Bodipy-
probes are superior compared to most other fluorescent labels, the costs are
high. When a reasonable price per sample in the receptor assay is needed, only
a small amount of the Bodipy probe can be incorporated, which will result in
decreased sensitivity caused by the lowering of fluorescence intensity.
4.4 Conclusions
From the results described in this Chapter, it can be concluded that fluorescent
lipids can be used to obtain highly fluorescent (proteo)liposomes. Since we
expect no interactions between the receptor and the fluorescent lipids, which
would allow a high degree of labeling, and because of economical reasons we
selected fluorescein DHPE as the lipid probe to be used in the receptor assay.
Fluorescein DHPE has a high excitation and emission wavelength, therefore it
is not expected that membrane constituents disturb the detection of the
fluorescent signal. Since a relatively high amount of the labeled lipids could be
co-reconstituted without quenching effects, a highly diluted labeled-liposomes
suspension could be easily detected. Therefore, the use of these fluorescent-
labeled liposomes in a receptor assay, where a small fraction of the total
proteoliposomes might bind to an immobilized ligand (see Chapters 5 and 6),
should present no problems with respect to fluorescent intensity.
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Further experiments should be done to optimize the procedure. The effects of
pH and the use of different buffers or even organic solvents might influence the
fluorescence characteristics. However, since biological molecules (e.g. receptor
proteins) are abundant in the preparations used, a pH close to the physiological
value (approximately pH 7.4) has to be chosen in order to assure proper
functioning of these bio-molecules. A drastic pH-change could be used,
however, when, for instance the receptor bound fraction is separated from the
free fraction and hence good functioning of the receptor is not needed for
detection of the fluorescence signal.
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In traditional radioreceptor assays, all components in the assay (receptor
proteins, (labeled) ligand and analyte) are incubated in vitro (solution-phase
RA) under the proper conditions, after which the bound and free fractions of
the ligand are separated (see Chapter 1). Alternatively, solid-phase receptor
assays have been developed, where (in most cases) the receptors are
immobilized on solid matrices, such as nitrocellulose membranes or microtiter
plates.
The main advantages of using solid-phase RA over conventional solution-phase
RA are:
1. Large sample numbers can be simultaneously tested with minimal effort.
2. Some investigators found that biological fluids did not interfere with the
binding characteristics of the immobilized receptor, therefore, unextracted
plasma or urine samples could be used (Nichols et al. (1992) and Suzuki et
al. (1992).
3. The solid phase containing the immobilized receptors may be used for
prolonged periods of time when used and stored under proper conditions,
without significant loss of sensitivity and specificity (Suzuki et al., 1992).
Suzuki et al. (1992) used Triton X-100 solubilized rabbit mammary prolactin
(PRL) receptors, subsequently purified by concanavalin A-agarose
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chromatography, and immobilized the purified receptors on a nitrocellulose
membrane. Because of the low protein binding capacity of nitrocellulose
membranes, purification of the receptors and the use of a labeled ligand with
high specific activity (125I-o-PRL) were necessary for quantitative detection of
receptor binding.
Crude bovine cerebella membranes were immobilized in 96-wells microtiter
plates by Nichols et al. (1992) for the quantitative receptor assay of endothelin.
Since only 10-20 µg of membrane protein was assayed in a small volume (100
µl), considerable savings in reagents could be realized. Endothelin
concentrations as low as 10−10 M could be reliably detected in serum samples
and the use of a 96-wells microtiter plate facilitated the rapid determination of a
large number of samples. However, since the receptor was not purified and the
total amount of immobilized protein was small (resulting in a low receptor
concentration), a high specific activity ligand (125I-endothelin) was needed.
Kaufman et al. (1993), immobilized the extracellular ligand binding domains of
the nerve growth factor receptor (NGF receptor), basic fibroblast growth factor
receptor (bFGF receptor) and the platelet-derived growth factor receptor
(PDGF receptor) by biotinylation of amino groups in the extracellular domains,
and coupling of the biotinylated domains to streptavidin-coated microtiter
wells. All three receptors retained high affinity (0.7-1.8 nM) for their respective
ligands. Moreover, the immobilized biotin-streptavidin-immobilized receptors
could be stored at −80°C for 1 year without decreases or changes in ligand
binding.
Besides immobilization of receptors, other methods for receptor assays have
been developed using solid supports. For instance, Tanaka et al. (1992)
developed a non-isotopic receptor assay for benzodiazepines using a solid-
phase avidin-biotin-binding assay. Competition of enzyme-labeled
(horseradish-peroxidase) avidin with immobilized biotin and biotin-labeled
ligands allowed for a sensitive determination of benzodiazepines. An identical
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assay was developed for the nicotinic acetylcholine receptor by the same
laboratory (Chen et al., 1992).
In this Chapter, we describe the development of a novel receptor assay utilizing
the benzodiazepine receptor (see Figure 5.1 for the principle of the assay). A
suitable benzodiazepine ligand (didesethylflurazepam) was, via a spacer arm,
immobilized on a 96-wells microtiter plate (Figure 5.1A). Coupling of the
ligand to the microtiter plate was done essentially as described by Sigel et al.
(1982) and Taguchi and Kuriyama (1984) for the preparation of an affinity
column for the purification of the benzodiazepine receptor. The choice of the
ligand to be immobilized is very critical, since various positions on the
molecule might be involved in the receptor-ligand binding, and are therefore
unavailable for the immobilization reaction. Moreover, when a suitable reactive
group on the molecule is available, immobilization (via a spacer arm) could
reduce the affinity of the ligand for the receptor. Didesethylflurazepam has a
primary amino group not involved in the receptor binding which can be used to
immobilize it (via a spacer arm) to a solid phase with retention of its high
affinity for the receptor, as described by Sigel et al. (1992).
The benzodiazepine receptor was solubilized from a calf brain homogenate (as
described in Chapter 2) and reconstituted in asolectin liposomes (see Chapter 3
for details about the followed procedure), and added to the wells of the
microtiter plate containing the immobilized didesethylflurazepam (Figure
5.1B). Labeled ligand ([3H]flunitrazepam) added to the incubation mixture
competed with the immobilized ligand for the same receptor binding site
(Figure 5.1C). Increasing the amount of labeled ligand will displace more
receptors initially bound to the immobilized ligand. When a fixed amount of
the incubation mixture is taken from the wells and transferred to (polyethylene)
tubes and an additional saturating amount of labeled ligand is added to these
samples, such that the final concentration is the same in every sample, a sort of
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saturation curve will be obtained, where the total amount of receptors in each
sample (Bmax) will be measured (saturation of all available binding sites by the
labeled ligand), after separation of the bound and free fractions of the labeled
ligand by filtration.
Figure 5.1 Principle of the radioreceptor assay with immobilized ligand-containing
microtiter plates. In step A, the ligands (triangles) are immobilized via spacer
arms (rods) to the solid phase. In step B, proteoliposomes containing the
benzodiazepine receptor (shaded circles) are added to the wells (1) and are
allowed to bind to the immobilized ligands (2). Proteoliposomes without the
benzodiazepine receptor (but possibly containing other receptors or membrane
proteins) are shown as black circles. Step C, shows the addition of free
(labeled) ligand (1), which competes with the immobilized ligand for the same
receptor binding plate (2). The amount of receptors ultimately bound to the
immobilized ligands (light gray circles) depends on the concentration of free
ligand added: Increasing the concentration of free ligand is resulting in a
decrease of the amount of receptors bound to the immobilized ligand.
A Novel Benzodiazepine Radioreceptor Assay Using a Immobilized Ligand-Containing Microtiter
Plate
81
Note that this concept is completely different compared to the traditional
radioreceptor assay, where the receptor concentration and the amount of
labeled ligand in the sample is kept constant, and addition of analyte will
ultimately (at higher concentrations of analyte ligand added) lead to saturation
of the receptor. The receptor assay described in this Chapter, starts as a normal
receptor assay, where the amount of analyte, in this case the ligand
immobilized to the wells of the microtiter plates is assumed to be constant, as is
the receptor concentration, while the amount of labeled ligand varies. After
withdrawal of part of the samples, an additional (second) radioreceptor assay is
carried out, where the amount of labeled ligand is constant (and no analyte is
present), but in which the receptor concentration is varying, depending on the
extent of displacement it has undergone in the first assay. In other words, when
a high concentration of labeled ligand is present in the well, the majority of
receptors (incorporated in liposomes) are in solution and the highest amount of
binding of the labeled ligand to the receptors will be found in de second
receptor assay, and vice versa. Therefore, the use of [3H]flunitrazepam, used as
labeled ligand, in this case merely serves to demonstrate the principle of the
assay, since the calculation of binding constants, as normally done in the
traditional assay, is not possible, due to the different set-up.
5.2 Materials and Methods
Materials
Bovine serum albumin (type 5, 96-99%), bovine globulins (Cohn fractions II
and III), benzamidine hydrochloride (97%), bacitracin (50,000 units/g), adipic
acid dihydrazide, a 240 mg/ml stock-solution of 1-ethyl-3- (3-
dimethylaminopropyl)-carbodiimide hydrochloride, sodium iodoacetate, N,N-
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dimethyl-formamide, 2-aminoethanol, cholic acid (98%) and sodium
deoxycholate (>95%) were obtained from Sigma (St. Louis, MO, USA).
Reacti-Bind maleic anhydride activated polystyrene 96-well microtiter plates
were from Pierce (Rockford, IL, USA). Soybean lipids (asolectin, i.e. crude
soybean extract containing approx. 20% PC) were from Avanti Polar Lipids
(Alabaster, AL, USA). [N-methyl-3H]flunitrazepam (82.0 Ci/mmol) was
obtained from DuPont NEN (Wilmington, DE, USA). Lorazepam was kindly
provided by Wyeth Laboratoria (Hoofddorp, The Netherlands). Polyethylene
glycol (PEG) 6000 was supplied by Genfarma (Maarssen, The Netherlands),
Sephadex G-50 Medium by Pharmacia Biotech (Uppsala, Sweden),
polyethylene tubes by Greiner (Alphen a/d Rijn, The Netherlands), and glass
fiber filters (GF/B) by Whatman (Maidstone, UK). Rialuma scintillation
cocktail was obtained from Lumac (Olen, Belgium). Other chemicals were of
analytical grade and were purchased from Merck (Darmstadt, Germany).
Preparation of the microtiter plate containing immobilized benzodiazepine
The coupling of the ligand to the microtiter plate was adapted from a protocol
used by Sigel et al. (1982) for the preparation of an affinity column for the
purification of the benzodiazepine receptor. In short, 200 µl 0.5 M adipic acid
dihydrazide (pH 7.5) was added to each well of a Reacti-Bind maleic
anhydride activated polystyrene 96-wells microtiter plate and incubated for 48
h at 35°C. The plate was washed twice by rinsing the wells with distilled water.
Incubating the wells with 200 µl 1 M 2-aminoethanol (pH 7.5) for 1 h at 35°C
blocked excess reactive sites on the plate. The plate was washed with distilled
water, 1 M NaCl and, again, distilled water. Each well was incubated with 200
µl 30 mM sodium iodoacetate (pH 5.0) and 50 µl 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride solution (pH 5.0) for 3 h at
35°C, followed by washing twice with distilled water. To all wells 100 µl 50
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mM sodium bicarbonate (pH 8.0) and 100 µl N,N-dimethylformamide,
containing 0.1 mg/ml didesethylflurazepam (Ro-7-1986) were added, and the
plate was incubated for 48 h at 35°C. Excess reactive linker sites were blocked
for 1 h at 35°C with 200 µl 1 M 2-aminoethanol (pH 7.5) After washing three
times with distilled water the plates were used immediately.
Preparation of brain membranes and solubilization of the benzodiazepine
receptor
The preparation of a calf brain membrane homogenate and the solubilization of
these membranes were done as described by Viel et al. (1997). Shortly, calf
brains (minus the cerebellum), obtained from the slaughterhouse, were stored at
−80°C. The material was thawed and homogenized in 5 volumes (v/w) of ice-
cold 0.32 M sucrose using a glass-PTFE Potter-Elvehjem homogenizer
(R.W.18, Janke & Kunkel, Staufen i. Breisgau, Germany) at 1200 rpm. The
homogenate was centrifuged at 1000 g for 10 min at 4°C. The supernatant was
carefully decanted and centrifuged for 60 min at 100,000 g at 4°C. The pellet
was washed twice with 50 mM phosphate buffer (pH 7.4) containing 1 mM
EDTA followed by centrifugation for 30 min at 100,000 g at 4°C. The final
pellet was suspended in 5 volumes of the same buffer, rapidly frozen in liquid
nitrogen and lyophilized for 48 h.
Lyophilized membranes were suspended to a protein concentration of 8 mg/ml
in ice-cold 50 mM Tris-HCl (pH 7.4, 22°C) supplemented with protease
inhibitors (1 mM benzamidine and 200 µg/ml bacitracin), 0.5 M KCl and 1 mM
EDTA and were solubilized on ice by dropwise addition of 20 mg/ml
deoxycholate (pH 7.6), to a final detergent concentration of 2 mg/ml. After 30
min, non-solubilized material was removed by centrifugation at 100,000 g for 1




Reconstitution of the solubilized benzodiazepine receptor into
proteoliposomes by size-exclusion chromatographic detergent depletion.
The procedure for the reconstitution of the solubilized benzodiazepine receptor
was done as described by Viel et al. (1997). Briefly, soybean lipids (asolectin)
were dissolved in chloroform and subjected to rotary evaporation in a round-
bottomed flask. Dissolution and evaporation was repeated twice with
diethylether and the lipid film was flushed with nitrogen. The lipids were
dispersed with 125 mM sodium cholate in 50 mM Tris-HCl (pH 8.0, 22°C) to
obtain a lipid concentration of 75 mg/ml (approximately 100 mM). A 1.5 ml
aliquot of the lipid solution was mixed with 2.5 ml of deoxycholate-solubilized
membranes and applied at 1.5 ml/min at 4°C on a 39 cm × 2 cm Sephadex G-
50 M gel bed in 50 mM Tris-HCl supplemented with 1 mM EDTA and 0.1 M
KCl (pH 7.6, 22°C). The void volume fractions containing the proteoliposomes
were collected and pooled. About half of the total solubilized protein added
was recovered in the proteoliposome suspension.
Protein determination
The amount of protein in the receptor preparations was determined by a
modified Lowry method (Clark, 1984) after protein precipitation by the
addition of trichloroacetic acid to avoid interference of detergent and Tris
(Bensadoun and Weinstein, 1976). Bovine serum albumin was used as a
standard and was treated as other samples.
Saturation binding experiment
Samples of the proteoliposome suspension [containing 80 µg protein in 180 µl
50 mM Tris-HCl supplemented with 1 mM EDTA and 0.1 M KCl (pH 7.6,
22°C)], were added to the wells of the immobilized benzodiazepine microtiter
plate and were incubated for 2 h at 0-2°C with 20 µl aliquots of
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[3H]flunitrazepam stock solutions (in 50 mM Tris-HCl (pH 7.6, 22°C)
supplemented with 1 mM EDTA) giving final concentrations of 0.1-10 nM
[3H]flunitrazepam. The total incubation volume was 200 µl. After incubation,
150 µl aliquots of the samples were transferred from the wells into
polyethylene tubes, the concentration of [3H]flunitrazepam in all samples was
adjusted to 10 mM. These samples were incubated further for 45 min at 0-2°C.
After the latter incubation, 15 µl of 33 mg/ml bovine globulins and 85 µl of a
360 mg/ml PEG-6000 solution were added. The incubation was continued for
another 12 min and then stopped by the addition of 3 ml of ice-cold 50 mM
Tris-HCl buffer (pH 7.6, 22°C) supplemented with 1 mM EDTA, after which
the samples were immediately filtered through Whatman GF/B glass fiber
filters under vacuum using a filtration apparatus (48S, University Centre for
Pharmacy, Groningen, The Netherlands). The tubes were rinsed twice with 3
ml portions of the same buffer, which were also filtered. The total filtration and
rinsing process of each separate tube was done within 15 s. The filters were
then transferred to scintillation vials and dispersed in 3.5 ml scintillation
cocktail by shaking for 2 h. The vials were counted for 40,000 counts or 5 min,
whatever came first, in a liquid scintillation counter (Minaxi, Packard,
Groningen, The Netherlands).
5.3 Results and Discussion
A benzodiazepine (didesethylflurazepam or Ro7-1986) was immobilized on a
maleic anhydride-activated polystyrene 96-wells microtiter plate via a
hydrophilic spacer of 15-atom length, three of which are originating from the
benzodiazepine itself (Figure 5.2). The procedure followed is essentially as
described by Sigel et al. (1982) for immobilizing didesethylflurazepam to
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agarose for affinity chromatographic purification of the benzodiazepine
receptor. Three major steps were involved in the immobilization procedure:
1. coupling of adipic acid dihydrazide (AAD) to the maleic anhydride-
activated microtiter plate
2. reaction between immobilized AAD and iodoacetate (using the
carbodiimide as a catalyst)
3. coupling of the benzodiazepine to the formed spacer
Didesethylflurazepam has a primary amino function on the N1 position that is
not involved in the interaction with the receptor. Besides, coupling of this
benzodiazepine via a spacer arm to a solid phase essentially does not alter its
affinity towards the receptor. Therefore, this ligand is suitable for
immobilization procedures. The length of the spacer arm is another critical
parameter. Since the binding site of a receptor is located inside the membrane
protein, the use of a short spacer arm (approximately 1-7 atoms length) or no
spacer at all, will yield a ligand immobilized such, that it can not reach the
binding site. The length of 15 atoms was chosen by Sigel et al. (1982) and
appeared to work properly for immobilization to an agarose column for
purification of the benzodiazepine receptor and, therefore, we chose this length
for our experiments.
N H N H C
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Figure 5.2 Structure of didesethylflurazepam (Ro7-1986) immobilized via a 15-atom
length spacer to a solid support (maleic anhydride activated polystyrene 96-
well microtiter plate).
The main difference between the immobilization procedure as described by
Sigel and the one described here is the reaction temperature. All reactions were
done at 35°C instead of room temperature. At room temperature, almost no
coupling of the benzodiazepine via the spacer to the microtiter plate was
observed.
Didesethylflurazepam in the concentration range 5x10−6 to 0.05 mg/ml (final
concentrations) was added to the (reactive) immobilized spacer. It was found
that 0.05 mg/ml was a suitable concentration to immobilize. When lower
concentrations were used, the amount of receptors that bound to the
immobilized ligand was too low, as determined with the radioreceptor assay
(results not shown). Higher concentrations were considered impractical, since
only a small amount of the ligand was available to our research group.
From the 3-step immobilization procedure, only the first step (the coupling of
AAD to the microtiter plate) could be (qualitatively) checked, with 2,4,6-
trinitrobenzenesulfonate (TNBS). The latter reacts with a primary amino group,
giving a yellow color.
Since no antibodies against didesethylflurazepam were available,
immobilization of this ligand via its spacer to the microtiter plate could only be
checked indirectly with a radioreceptor assay. However, because the ligand was
immobilized, an alternative radioreceptor assay had to be developed:
proteoliposomes were bound to the immobilized ligand and, when
[3H]flunitrazepam was added, there was competition between the radiolabeled
ligand and the immobilized ligand for the receptors. Hence, increasing
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concentrations of the radiolabeled ligand would remove receptors from the
immobilized ligand back into the solution. As a result, a higher receptor
concentration can be found in the samples containing higher concentrations of
[3H]flunitrazepam. After incubation at 0°C for 2 h, 150 µl samples were
transferred from the wells to a polyethylene tube, and the concentration of
[3H]flunitrazepam in all samples was adjusted to 10 mM to provide a large
excess, thus making sure that a constant percentage (>80%) of the receptors in
the solution are radioactively labeled. The labeled receptors were then filtered
off on glass fiber filters and the radioactivity on the latter was counted. Thus, in
this type of receptor assay the amount of receptor in the sample solution is
determined. Figure 5.3 shows the results of the above described receptor assay.
The IC50, in this case the amount of labeled ligand that could displace 50% of
the receptors bound to the immobilized ligand, can be expressed as:
Since the concentration of free, immobilized, ligand (F(immobilized)) is
approaching 0 (in the microtiter plate only a very small layer near the solid
phase contains this ligand, while in the bulk solution (and in the samples
transferred to polyethylene tubes for the further incubation) this ligand is
absent), the IC50 should equal the value of the Kd of flunitrazepam. As seen in
Chapter 3, the Kd of flunitrazepam was 2.8 nM for benzodiazepine receptors
reconstituted in asolectin proteoliposomes, whereas it can be estimated from
Figure 5.3 to be approximately 0.5 nM.
Since this receptor assay is different from the normal assay, it is not possible to
(accurately) calculate all receptor binding constants. For the latter, the receptor
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only shows that the principle of a receptor assay based upon immobilized
ligand binding to receptors incorporated in liposomes works properly.
Procedures for the reconstitution of other receptors and immobilization
protocols have been described in the literature (see Chapter 3). It can be
expected that the above assay set-up can also be used for other receptors than
the benzodiazepine receptor.
Figure 5.3 Radioreceptor assay after a competition between ligand immobilized to a
microtiter plate and radioligand ([3H]flunitrazepam) for benzodiazepine receptors. See text for
details. Results are the means of two separate experiments.
Based on the above observations, a quantitative receptor assay may be
developed using fluorescent labeled proteoliposomes, in which the amount of
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receptors bound to the solid phase-immobilized ligand can be measured
directly and more accurately (see Chapter 6).
5.4 Conclusions
Immobilization of a benzodiazepine (didesethylflurazepam) to a microtiter
plate can be used to develop a solid phase receptor assay, in which the receptor
is incorporated in liposomes. The immobilization procedure could be easily
adapted from the protocols available for immobilization of benzodiazepine
ligands on an affinity column for chromatographic purification of the receptor.
Competition between the added (labeled) ligand and the immobilized ligand for
the receptor binding site, takes place in a small volume (the area near the walls
of the microtiter plate). As a result, the sensitivity of the assay is higher, since
the concentration of free, immobilized ligand does not play a role in the
calculation of the IC50 value. This leads to lower values of the IC50 compared to
the traditional radioreceptor assay. The receptors were incorporated into
proteoliposomes, since the latter can be easily labeled with fluorescent lipids
(Chapter 4) for the development of a non-radioactive receptor assay (see
Chapter 6), but the assay should work equally well when membrane
suspensions (crude homogenate) are used.
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A Novel Fluorescent Benzodiazepine
Receptor Assay Using Fluorescent
Labeled Proteoliposomes and a
Ligand Immobilized in Microtiter
Plates
6.1 Introduction
Receptor assays are routinely used for the assessment of the interaction of
(new) chemical entities with a given receptor as well as for the quantitation of
drugs that exert their action via a particular receptor. Due to the fact that in
general the binding of a compound to a receptor cannot be quantitated directly,
labeled ligands with high affinity towards the receptor are being used.
Competition between the labeled ligand and the analyte for the same receptor
binding site will take place in the sample and can be monitored by quantitation
of either the free or the receptor- bound fraction of the labeled ligand. Most
labeled ligands used in receptor assays are radioligands. The major advantage
of using radioligands (mainly tritium and iodine labeled ligands) in receptor
assays is that the spatial structure of the ligand is not or only slightly modified
by the incorporation of an isotope. Therefore, the affinity of the labeled ligand
can be expected to be comparable or even identical to that of the unlabeled
compound. Besides, radioligands are chemically stable and can be detected
with a high sensitivity and over a wide concentration range. However, there are
several disadvantages in using radiolabels, including high costs, radioactive
waste, health hazards, and the need of special equipment and licenses. For these
reasons fluorescent labels for the use in receptor assays have been developed,
as described for the α- and β-adrenergic and the opiate receptor by Corrêa et
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al., (1980), the benzodiazepine receptor (Takeuchi and Rechnitz, 1991, and
Janssen, 1997) and the estrogen receptor (Hwang et al., 1992). Because most
high affinity ligands available do not have native fluorescence, fluorescent
functionalities are to be coupled directly or via a (chemical) spacer-arm to the
ligand. However, the attachment of a (bulky) fluorescent moiety to a ligand
often results in diminished affinity of the ligand to its receptor. Moreover, since
ligands are bound inside the receptor protein, many positions on the ligand are
unsuitable for the attachment of fluorescent labels. For example, coupling of
fluorophores to 1,4-benzodiazepines and 1,2-annelated analogs, either at the 3-
or 7-position (Figure 6.1), resulted in a substantial decrease in affinity of that
benzodiazepine towards its receptor, whereas labeling at the 1-position may
yield a similar or slightly lowered affinity (Janssen, 1997).
Figure 6.1 Basic structures of 1,4-benzodiazepines (left) and 1,2-annelated 1,4-
benzodiazepines (right).
The development of high affinity fluorescent labeled ligands is merely a matter
of trial and error, because hardly any relevant Structure Activity Relationships
are available for ligands containing bulky groups. Furthermore, background
fluorescence caused by the proteins present in the receptor preparation may
overshadow the changes in fluorescence that can be ascribed to changes in the
bound or free fraction of the labeled ligand. Therefore, it would be preferable to




























This Chapter describes the development of such a novel fluorescent
benzodiazepine receptor assay. Receptors incorporated in fluorescent
liposomes (see Chapter 4) can be bound to a benzodiazepine immobilized to a
microtiter plate (as already described in Chapter 5). Competition with analyte
present in the sample will lead to a decrease in the amount of receptor bound to
the immobilized ligand and, hence, in a decrease in the amount of fluorescence
that can be detected after washing of the plate. Figure 6.2 shows a schematic
presentation of the method.
Instead of labeling the ligands, the receptors are (indirectly) labeled in this
method. Since there is no need to label the ligands with bulky fluorescent
moieties, we expect that no dramatic decrease in affinity will be seen, although
the immobilized ligand might have a somewhat lower affinity towards the
receptor. Because many fluorescent lipids are present per single receptor, low
receptor concentrations can be used and quantitated with high precision.
Theoretically, this might improve the limits of detection and quantitation.
Figure 6.2 Principle of the fluorescent receptor assay, where receptors incorporated in
fluorescent labeled liposomes compete between ligand immobilized on a
microtiter plate and the analyte present in the sample. Step 1: to a microtiter
plate containing immobilized ligands (A), proteoliposomes are added (B) and
incubated under proper conditions, until most receptors are bound to the
immobilized ligand in the wells (C). In step 2, competition with analyte
present in the sample that is being added (D) leads to an equilibrium situation,
where part of the receptor-containing proteoliposomes are bound to the
immobilized ligand, and part of them are bound to the analyte (E). After
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washing, fluorescence can be determined in the well and is a (reversed)
measurement for the amount of analyte that was present in the sample (F).
6.2 Materials and Methods
Materials
Bovine serum albumin (type 5, 96-99%), bovine globulins (Cohn fractions II
and III), benzamidine hydrochloride (97%), bacitracin (50,000 units/g), adipic
acid dihydrazide, 1-ethyl-3- (3-dimethylaminopropyl)carbodiimide
hydrochloride, sodium iodoacetate, N,N-dimetyl-formamide, 2-aminoethanol,
cholic acid (98%) and sodium deoxycholate (>95%) were obtained from Sigma
(St. Louis, MO, USA). Reacti-Bind maleic anhydride activated polystyrene
96-well microtiter plates were from Pierce (Rockford, IL, USA). Soybean
lipids (asolectin, i.e. crude soybean extract containing approximately 20%
phosphatidyl choline) were from Avanti Polar Lipids (Alabaster, AL, USA), N-
(5-fluoresceinthiocarbamoyl)-1,2-dihexa-decanoyl-sn-glycero-3-
phosphoethanolamine, triethyl-ammonium salt (fluorescein DHPE) was from
Molecular Probes, Inc. (Eugene, OR, USA). Lorazepam was kindly provided
by Wyeth Laboratoria (Hoofddorp, The Netherlands). Sephadex G-50
Medium was supplied by Pharmacia Biotech (Uppsala, Sweden). Other
chemicals were of analytical grade and were purchased from Merck
(Darmstadt, Germany).
Preparation of microtiter plates containing immobilized benzodiazepine
Coupling of the ligand to the microtiter plate was done essentially as described
by Sigel et al. (1982) and Taguchi and Kuriyama (1984) for the preparation of
an affinity column for the purification of benzodiazepine receptors with some
minor modifications (see Chapter 5). In short, to each well of a Reacti-Bind
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maleic anhydride activated polystyrene 96-well microtiter plate, 200 µl 0.5 M
adipic acid dihydrazide (pH 7.5) was added and incubated for 48 h at 35°C.
The plate was washed twice by rinsing the wells with distilled water.
Incubating the wells with 200 µl 1 M 2-aminoethanol (pH 7.5) for 1 h at 35°C
blocked excess reactive sites on the plate. The plate was washed with distilled
water, 1 M NaCl and, again, distilled water. Each well was incubated with 200
µl 30 mM sodium iodoacetate (pH 5.0) and 50 µl (from a 240 mg/ml stock
solution of) 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
(pH 5.0) for 3 h at 35°C, followed by washing twice with distilled water. To all
wells 100 µl 50 mM sodium bicarbonate (pH 8.0) and 100 µl N,N-
dimethylformamide, containing 0.1 mg/ml didesethylflurazepam (Ro-7-1986)
were added, and the plate was incubated for 48 h at 35°C. The plates were
subsequently incubated for 1 h at 35°C with 200 µl 1 M 2-aminoethanol (pH
7.5) in order to block the excess of reactive linker sites. After washing three
times with distilled water, the plates were used immediately.
Preparation of brain membranes and solubilization of the benzodiazepine
receptor
The preparation of a calf brain membrane homogenate and the solubilization of
these membranes were done as described by Viel et al. (1997). Shortly, calf
brains (minus the cerebellum), obtained from the slaughterhouse, were stored at
−80°C. The material was thawed and homogenized in 5 volumes (v/w) of ice-
cold 0.32 M sucrose using a glass-PTFE Potter-Elvehjem homogenizer
(R.W.18, Janke & Kunkel, Staufen i. Breisgau, Germany) at 1200 rpm. The
homogenate was centrifuged at 1000 g for 10 min at 4°C. The supernatant was
carefully decanted and centrifuged for 60 min at 100,000 g at 4°C. The pellet
was washed twice with 50 mM phosphate buffer (pH 7.4) containing 1 mM
EDTA followed by centrifugation for 30 min at 100,000 g at 4°C. The final
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pellet was suspended in 5 volumes of the same buffer, rapidly frozen in liquid
nitrogen and lyophilized for 48 h.
Lyophilized membranes were suspended to a protein concentration of 8 mg/ml
in ice-cold 50 mM Tris-HCl (pH 7.4, 22°C) supplemented with protease
inhibitors (1 mM benzamidine and 200 µg/ml bacitracin), 0.5 M KCl and 1 mM
EDTA and were solubilized on ice by dropwise addition of 20 mg/ml
deoxycholate (pH 7.6), to a final detergent concentration of 2 mg/ml. After 30
min, non-solubilized material was removed by centrifugation at 100,000 g for 1
h at 4°C. The amount of protein in the solubilized preparation was
approximately 5 mg/ml.
Reconstitution of the solubilized receptor into fluorescent proteoliposomes,
by size-exclusion chromatographic detergent depletion.
Reconstitution of the benzodiazepine receptor in (fluorescent) asolectin
liposomes was done as described by Viel et al. (1997). In short, 150 mg
soybean lipids (asolectin) and 250 µg fluorescein-DHPE (used as fluorescent
lipid probe) were dissolved in chloroform and subjected to rotary evaporation
in a round-bottomed flask. Dissolution and evaporation was repeated twice
with diethylether and the lipid film was flushed with nitrogen. The lipids were
dispersed with 125 mM sodium cholate in 50 mM Tris-HCl (pH 8.0, 22°C) to
obtain a lipid concentration of 75 mg/ml (approximately 100 mM). A 1.5 ml
aliquot of the lipid solution was mixed with 2.5 ml of deoxycholate-solubilized
membranes and applied at 1.5 ml/min at 4°C on a 39 cm × 2 cm Sephadex G-
50 M gel bed in 50 mM Tris-HCl supplemented with 1 mM EDTA and 0.1 M
KCl. The void volume fractions, containing the proteoliposomes, were
collected and pooled (approximately 15 ml total), and were used immediately
for further experiments (alternatively, the proteoliposomes could be stored at
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−20°C or −80°C, as described in Chapter 3). About half of the total solubilized
protein was recovered in the proteoliposome suspension.
Protein determination
The amount of protein in the receptor preparations was determined by a
modified Lowry method (Clark, 1984) after protein precipitation by the
addition of trichloroacetic acid to avoid interference of detergent and Tris
(Bensadoun and Weinstein, 1976). Bovine serum albumin was used as standard
and was treated as other samples.
Binding experiments
Samples of the fluorescent-labeled proteoliposome suspension [containing 80
µg protein in 180 µl 50 mM Tris-HCl supplemented with 1 mM EDTA and 0.1
M KCl (pH 7.6, 22°C)], were added to the wells of the microtiter plate with
immobilized benzodiazepine and were incubated for 2 h at 4°C with 20 µl
aliquots of lorazepam stock solutions (in 50 mM Tris-HCl (pH 7.6, 22°C)
supplemented with 1 mM EDTA) giving final lorazepam concentrations of 300
nM-30 pM. The total volume was 200 µl. After this incubation-period, the plate
was washed three times with ice-cold Tris/EDTA buffer and the bound
(fluorescent) proteoliposomes were measured in a BioTek FL500 microplate
fluorescent  reader (Winooski, VT, USA), using an excitation wavelength of
496 nm and an emission wavelength of 519 nm.
6.3 Results and Discussion
Principle of the fluorescent receptor assay
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The principle of this alternative fluorescent receptor assay, using a microtiter
plate to which didesethylflurazepam was immobilized, is depicted in Figure
6.2.
Benzodiazepine receptors reconstituted in asolectin liposomes also containing
fluorescein-DHPE as the fluorescent label (Chapter 4) were bound to
benzodiazepine ligands (didesethylflurazepam) immobilized on a microtiter
plate (Chapter 5). The incubation time was prolonged (2 h total) because the
ligand may not have been homogeneously distributed, therefore the association
time of the binding of (immobilized) ligand to its receptor might be longer than
in a homogeneous receptor binding assay. Further experiments are required to
confirm this. Competition with analyte (lorazepam) present in the incubation
mixture led to a reduction in binding of the receptor to the immobilized ligand,
depending on the concentration of analyte present in the sample. An increase in
the concentration of the analyte causes a proportional decrease in the amount of
receptors bound to the immobilized ligand. Since the receptors are incorporated
in fluorescent-labeled liposomes, the amount of fluorescence that can be
detected after washing the plate, is an inverse measure of the concentration of
analyte present in the sample.
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Figure 6.3 Inhibition curve: Fluorescent proteoliposomes containing the benzodiazepine
receptor were incubated with a fixed amount of immobilized ligand in the
presence of increasing concentrations of a competitive ligand, lorazepam. The
results of two separate experiments are presented in the figure.
Binding experiments
Proteoliposomes containing the benzodiazepine receptor and fluorescein DHPE
were added together with 300 nM-30 pM lorazepam (which was used as the
analyte) to the wells of an immobilized didesethylflurazepam microtiter plate.
After a 2 h incubation period at 4°C the wells were washed three times with
ice-cold 50 mM Tris-HCl supplemented with 1 mM EDTA and the amount of
fluorescence was measured on a fluorescence plate reader. The inhibition curve
is shown in Figure 6.3.
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The IC50-value for lorazepam as determined with this assay is estimated as
approximately 0.2 nM, which is considerably lower than the values determined
by Janssen (1997) for a fluorescent receptor assay (FRA) or for the
radioreceptor assay (RRA), which were 7.2±0.5 nM and 6.6±0.7 nM,
respectively, which is approximately a factoe 30. A possible explanation is that
the association binding constant of immobilized ligand is (much) lower or the
dissociation binding constant of immobilized ligand is (much) higher than the
binding constants of lorazepam in solution. To check these possibilities, the
amount of didesethylflurazepam immobilized in the wells of the microtiter
plate and the association and dissociation binding kinetics of immobilized
didesethylflurazepam to the benzodiazepine receptor have to be determined in
more detail. However, as seen in Chapter 5, the saturation curve of
[3H]flunitrazepam in the microtiter plate, also showed a lowering in the IC50-
value. Due to the set-up of the experiment, in which competition between
immobilized ligand and analyte only takes place in the vicinity of the walls of
the wells, an increase in sensitivity can be anticipated. The factor 30 gain in
sensitivity found, therefore, might be caused by an increase in affinity of the
receptor on the one hand, and an additional increase in sensitivity caused by
amplification of the fluorescence signal, due to the presence of several
fluorescent lipids per single receptor protein. As a consequence, the detection
limit for benzodiazepines is lowered.
The nonspecific binding of fluorescent proteoliposomes (determined as the
amount of fluorescence present (after washing) in the plates incubated with an
excess concentration of lorazepam) was approximately 25%, which is
comparable to fluorescent receptor assays utilizing fluorescent ligands




The benzodiazepine receptor assay could be performed successfully in a
modified version, in that the ligand (didesethylflurazepam) was immobilized in
the wells of a microtiter plate and the receptor was present in the aqueous
medium, incorporated in fluorescent proteoliposomes. When an aliquot
containing the analyte was added, the latter competed with the immobilized
ligand in the binding with the receptors in the proteoliposomes. Further
experiments are needed to optimize the assay and to validate it. When the
amount of ligand immobilized in the wells is determined and optimized, the
amount of receptors can be chosen so that the accuracy and sensitivity are
optimal. However, at this time, already an increase in sensitivity of a factor 30
has been found, compared to receptor assays using a fluorescent ligand. The
time to perform the immobilized ligand receptor assay is still longer than in the
conventional assay, due to the prolonged incubation time. Further kinetic
studies should reveal if the incubation period could be shortened. Nonspecific
binding was comparable to fluorescent receptor assays using fluorescent-
labeled ligands, and might be reduced when a more purified receptor material is
used for the preparation of the proteoliposomes. Also, the walls of the
microtiter plate may be coated to prevent nonspecific binding of
proteoliposomes to the solid phase.
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In this thesis the development of a novel fluorescent receptor assay is
described. Thus far, most attempts to develop a nonradioactive receptor assay
were focused on the labeling of the ligand of choice by coupling a (large)
detectable moiety to it. Since various positions on the ligand are involved in the
actual receptor binding, more often than not this approach leads to reduction or
elimination of the affinity of that ligand towards its receptor. For that reason,
the selection of a suitable ligand and the construction of a labeled ligand with
high affinity can be laborious and the expenses might be high.
Therefore, our goal was to construct a receptor assay, in which there was no
need to label the ligand. Instead, we set out to label the receptor. To do this, we
immobilized a suitable benzodiazepine ligand (didesethylflurazepam) via a
hydrophilic spacer of 15-atom length (three of which originate from the
benzodiazepine molecule) to a maleic anhydride-activated polystyrene
microtiter plate. A brain membrane homogenate was solubilized with sodium
deoxycholate and the benzodiazepine receptors were reconstituted together
with fluorescent lipids in asolectin liposomes. The resulting proteoliposomes,
containing the benzodiazepine receptor and analyte (lorazepam in increasing
concentrations) were added to the wells of the microtiter plate. The analyte and
the immobilized ligand compete for binding to the receptor, incorporated in the
labeled liposome. Increasing concentrations of analyte in the sample reduced
the amount of fluorescent liposome-receptor complex bound to the
immobilized ligand in the well. After removing the supernatant, the
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fluorescence in the well was found to be inversely related to the concentration
of analyte in solution.
Binding of the labeled proteoliposomes containing the benzodiazepine receptor




LI = immobilized ligand
R* = proteoliposomes containing the receptor and the fluorophore
LIR
* = fraction of labeled proteoliposomes bound to the immobilized ligand
When an analyte is added the following equation describes the process:
LI + R
* + A ↔ LIR
* + AR* (2)
A = analyte
AR* = fraction of labeled proteoliposomes bound to the analyte, and
present in the supernatant
If a labeled proteoliposome does not contain a receptor it will not bind to the
immobilized ligand. Probably the number of liposomes that contain receptor
proteins is relatively small, considering the size of the receptor protein (Mr ≈
300,000, or approximately 5 nm) in comparison with the average size of the
liposomes (approximately 75 nm).
In this approach the fraction LIR
* in (2) was monitored, the amount of this
fraction is inversely related to the concentration of analyte. Ensing et al. [1,2]
compared the accuracy and precision profiles for radioreceptor assays in which
either the bound or the free fraction of labeled ligand were quantitated and
related to the concentration of analyte. Provided that a substantial part of the
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labeled ligand (>50%) was receptor-bound in the absence of analyte,
measurement of the free fraction of labeled ligand in the supernatant, collected
after a centrifugation step, improves the precision for low analyte
concentrations. For higher analyte concentrations, measurement of the bound
fraction labeled ligand, collected after a filtration step, is the preferred option.
If the situation should occur in which each proteoliposome contains at least 1
active receptor protein (and, assuming that the there is an excess immobilized
ligand capable of binding the majority of the receptor proteins), measurement
of the fraction labeled proteoliposomes, present in free form or complexed with
the analyte, is a viable option for this type of receptor assay. However, since a
considerable proportion of the proteoliposomes has relatively small sizes, as
determined in Chapter 3, they simply cannot contain the large benzodiazepine
receptor complex, therefore causing a high background fluorescence signal in
the free fraction. Besides, it can be estimated (assuming an average diameter
for the proteoliposomes of 75 nm) that 1 receptor protein per 750
proteoliposomes is present. It is therefore preferred to measure the fraction of
receptors bound to the immobilized ligand in this assay.
Immobilization of ligands
Methods have been developed for the preparation of columns for the affinity
chromatographic purification of receptors, which could be easily adapted for
the immobilization of ligands to solid phases. In our case, a benzodiazepine
was immobilized to a maleic anhydride-activated polystyrene microtiter plate
(see Chapter 5). Because such (affinity chromatographic) protocols are also
available for the purification of other receptors (examples can be found in Refs.
3-7), it can be expected that microtiter plates with suitable immobilized ligands
can also be developed for a variety of other receptors.
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One drawback of the present immobilization method is that it is not easy to
determine the amount of ligand that is bound to the plate after immobilization
without the availability of e.g. antibodies directed against that ligand. In our
case, we do not actually know how much ligand was immobilized per well, but
we immobilized increasing concentrations of ligand and selected that
concentration that gave the highest amount of specific binding (total binding −
non-specific binding) to the benzodiazepine receptor, as measured in the
receptor assay. In principle, ligands with the highest affinity towards the
receptor are preferable for immobilization. For example, the benzodiazepine
ligand 1012-S has a very high affinity for the benzodiazepine receptor and has
been used successfully for the development of an affinity column for the
purification of the receptor complex. It should be noted, however, that the
binding affinity of an immobilized ligand to the receptor might be different
from the affinity of the same ligand in solution. Even inactive precursors or
metabolites of high affinity compounds may be used, when coupling of the
spacer arm introduces functionalities required for high affinity interaction.
Labeled liposomes
Since receptors were found to be rather unstable when solubilized from
membrane fragments of the brain homogenate, liposomes were used to provide
a more stable embedding environment and to incorporate suitable detection
labels. The rationale behind this is to obtain small spherical particles (100-500
nm diameter) with one single or a few receptor proteins, together with a large
quantity of detectable functionalities. Since brain membranes do not fulfill this
requirement, (partial) purification of the receptor proteins is the next step.
For various membrane proteins, solubilization- and reconstitution procedures
have been described (Table 7.1 and Table 7.2). The solubilization of
membrane-bound receptors is the most critical step, since the use of detergents,
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necessary to separate the proteins from their lipid environment, can easily lead
to denaturation of the
Table 7.1 Conditions for solubilization of different types of membrane receptors from
animal tissue or cell cultures. a : besides detergents protease inhibitors were
used. The incubation temperature was 0-4°C except for digitonin (room
temperature). For other conditions, see Chapter 2.
receptor tissue     detergenta   recovery of receptor
reference
           binding
benzodiazepine bovine cortex 20 mM CHAPS 67%   8
benzodiazepine rat brain cortex 0.7% Triton X-100 60-70%   9
benzodiazepine bovine cortex 2% desoxycholate 54±6% 13
histamine H-1 guinea pig brain 1% digitonin 40-60%              10
µ-opioid 7215c cells 10 mM CHAPS 40±5% 11
muscarinic      bovine cortex 1% digitonin 34% 12
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Table 7.2 Reconstitution of membrane receptors in lipid vesicles. a : abbreviations used:
PC = phosphatidyl choline, Ch = cholesterol, Cholh = cholesteryl
hemisuccinate. b : SEC = size exclusion chromatography, also known as gel-
filtration. c : the myometrial oxytocin receptor binding activity after
reconstitution was dependent on the addition of cholesterol; without
cholesterol receptor binding could not be restored.
receptor lipids useda    method use for reference
detergent depletion
benzodiazepine asolectin SECb        13
benzodiazepine brain lipid extract SECb        14
myometrial oxytocin PC/Ch/Cholhc    bio-beads SM-2        15
vasopressin asolectin SECb        16
opioid brain lipids   PEG precipitation        17
receptors and therefore impair their capacity to bind pharmacologically active
substances. The use of mild detergents and detergent concentrations as low as
possible are hence important determinants. We used sodium deoxycholic acid
for solubilization of the crude brain membrane homogenate (Chapter 2).
Although this detergent is fairly aggressive, since it is ionic, it yielded higher
amounts of soluble receptors than other detergents.
Still, even at low concentrations of deoxycholate, a substantial loss of receptor
binding was observed after solubilization. This indicated that only a certain
amount of the receptor proteins were solubilized and/or that the receptor
binding was impaired to some extent.
The reconstitution of the solubilized benzodiazepine receptor into
proteoliposomes by size-exclusion chromatography was found to be less
critical (Chapter 3). Since it is a fast procedure, the exposure time of the
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receptor proteins to detergents was limited to a minimum, in contrast to
dialysis. As with many other receptors, the type of lipids used for the
reconstitution had little influence on receptor activity although the best results
were obtained with a mixture of phospholipids (asolectin).
Solubilization followed by reconstitution of membrane proteins could thus be
used to make lipid vesicles that contain the receptor of interest plus a label that
allows simple and sensitive detection and quantitation of the receptor-vesicle
complex. However, the amount of (active) receptor proteins after solubilization
and reconstitution was considerably lower than found in the initial membrane
homogenate; i.e. maximally only about 30% of the benzodiazepine receptors
could be recovered in liposomes. Purification of the receptor, for instance by
affinity chromatography might be used to increase the receptor density in the
liposome population. Additional advantages of the latter are that, since other
(interfering) proteins are not incorporated, the amount of nonspecific binding
consequently will be lowered, and that a higher receptor density in the
liposomes may allow further miniaturization of the assay. Ideally, each
liposome should contain one active receptor in order to obtain maximal assay
sensitivity.
Alternatively, proteoliposomes might be made without prior solubilization of
the membrane proteins. Preliminary results with sonication showed that
membrane vesicles could be formed directly from crude membrane
homogenate. Furthermore, sonication in combination with freezing and
thawing, followed by extrusion of the vesicles through membrane filters might
yield a more homogeneously sized population of proteoliposomes.
Fluorescent lipids could be co-reconstituted in the above approach, thus
forming labeled proteoliposomes (see Chapter 4). In principle, a large variety
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of labels can be included in the membranes of the proteoliposomes, including
radiolabeled lipids or enzymes (Figure 7.1). Alternatively, the (aqueous)
interior of the proteoliposomes can be filled with suitable labels, like
chromophores or soluble enzymes. However, one has to take measures to
prevent such proteoliposomes from leaking.
Radiolabels, preferably 3H or 125I, attached to e.g. the lipids, remain attractive
as a form of labeling, since large numbers of labels per liposome, and therefore,
per receptor binding site, can be obtained. Moreover, quantitation of bound
and/or free fractions of radiolabeled liposomes is relatively simple and reliable.
In addition, considering the availability of multi-channel detectors, high
throughput can also be warranted. However, widespread use of a radioactive
approach is limited because of legal limitations in the use of radioactive
substances and the disposal of radioactive waste. Thus, nonradioactive
functionalities remain preferable.
Functionalities that can readily be detected with spectroscopic (preferably
fluorescent or chemiluminescent techniques) therefore have a better practical
potential. In contrast to traditional receptor assays with fluorescent labeled
ligands, the selection of the fluorophore for the labeling of proteoliposomes is
not affected by a possible effect on receptor binding properties. Thus, any
fluorophore with favorable spectroscopic properties can be used. Favorable
spectroscopic properties are an emission wavelength and, preferably, an
excitation wavelength of the fluorophore longer than 450 nm in order to limit
background fluorescence by membrane proteins that are also reconstituted in
the liposomes. We selected a fluorescein-labeled phosphatidylethanolamine
(fluorescein-DHPE) as the fluorescent lipid, which was mixed with the lipids
used for the reconstitution process (asolectin). As a result the fluorescence label
was about 0.2% of the total lipid content. Higher label concentrations yielded
higher fluorescence signals but it also introduced some quenching.
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A different type of detectable functionality, offering new opportunities for the
reduction in sample size and for improving method sensitivity is formed by
enzymes. The latter can be incorporated in liposomes containing the receptor of
interest and amplify a signal by converting a precursor into a detectable
product, preferably of fluorescent or chemiluminescent nature. Examples of
such enzymes are monoamine oxidase and alkaline phosphatase. An assay
based on luciferase may also have high potential, in that only an increase in
signal, and virtually no background signal, is obtained.
However, fluorescent lipids are commercially available for reasonable prices
and are easy to incorporate in the liposomes. Detection can be obtained in a
single step, in contrast to using enzymes as the detection mode.
A major benefit of the approach presented here is that much smaller amounts of
receptors can be used, because a multitude of label (at least 50) is present per
single receptor protein and because the area in which receptor binding occurs is
restricted to the surface of the wells (Chapter 6). Therefore, miniaturization of
the assay is an option, which is particularly beneficial when materials are
scarce or expensive. The use of microtiter plates allows automation (of a large
part) of the receptor assay.
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Figure 7.1 Schematic presentation of the solubilization of membrane receptors (Step 1)
and their reconstitution in liposomes (Step 2A), together with appropriate
detection labels, such as fluorescent lipids (Step 2B) or enzymes (Step 2C).
After removal of the receptor-containing proteoliposomes, the microtiter plates
with immobilized ligand can be reused. In Chapter 6 it was shown that the
 sensitivity, in terms of IC50 values, of this heterogeneous assay is higher by a
factor of 30 than that obtained in homogeneous radioactive and non-radioactive
assays with benzodiazepine receptors [18]. This gain in sensitivity may to some
extent be explained by the low receptor concentration present, because there is
no depletion of analyte by its receptor binding. Another factor is the
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heterogeneous set-up of the assay. Competition for receptor binding between
the analyte and the immobilized ligand only occurs in the diffusion layer of the
wells in the microtiter plate. Over 99% of the receptor-containing
proteoliposomes were bound to the immobilized ligand in the absence of
analyte. This indicates that there is excess immobilized ligand relative to the
amount of receptors and eventually also a high affinity. Because quantitative
data concerning the amount of immobilized ligand per well were not available,
no affinity for the immobilized ligand could be calculated.
Because low amounts of drugs can be detected, interference of biological
matrices (e.g. plasma or urine) which frequently cause problems in the
conventional receptor assay, are less of a problem in this novel receptor assay.
Where normally a sample pretreatment step, such as solid phase extraction,
would be needed to eliminate the presence of these interferences, a dilution of
the biological sample could be enough to minimize the unwanted matrix effects
in the receptor assay described in this thesis.
The procedure may be further improved by reducing the nonspecific binding;
for example, using a further purified receptor preparation, selection of other
microtiter plate materials, coating of the plate surface, addition of competing
reagents in the incubation mixture, washing procedures or combinations
thereof.
In conclusion, the fluorescent receptor assay described in this thesis appears to
be a promising alternative for the conventional radioreceptor assay, as well as
for nonradioactive receptor assays in which ligands are labeled by coupling
with an easily measurable (e.g. fluorescent) functionality. Yet, additional





1. Ensing, K. (1984) "Bioanalysis of anticholinergics with muscarinic
receptors in relation with chronic obstructive lung diseases". Ph.D. thesis,
Groningen, The Netherlands.
2. Ensing, K., Feitsma, K.G., Bloemhof, D.A., In 't Hout, W.G. en de Zeeuw,
R.A. (1986) Centrifugation or filtration in quantitative radioreceptor assays.
J. Biochem. Biophys. Meth. 13, 85-96.
3. Miller, L.J., Hadac, E.M., Gates, L.K. and Gaisano, H.Y. (1992) Binding of
a phenetyl ester analogue of cholecystokinin to the solubilized pancreatic
cholecystokinin receptor: use in ligand-affinity chromatography. Biochem.
Biophys. Res. Comm. 183, 396-404.
4. Hugues, M., Crane, M.R., Thomas, B.R., Robertson, D., Gazzano, H.,
O'Hanley, P. and Waldman, S.A. (1992) Affinity purification of functional
receptors for Escherichia coli heat-stable enterotoxin from rat intestine.
Biochemistry 31, 12-16.
5. Clagett-Dame, M., Schoenleber, R., Chung, C. and McKelvy, J.F. (1989)
Preparation of an affinity chromatography matrix for the selective
purification of the dopamine D2 receptor from bovine striatal membranes.
Biochim. Biophys. Acta 986, 271-280.
6. Weber, D.V., Keeney, R.F., Familletti, P.C. and Bailon, P. (1988) Medium-
scale ligand-affinity purification of two soluble forms of human interleukin-
2 receptor. J. Chromatogr. 431, 55-63.
7. Govindan, M.V. and Gronemeyer, H. (1984) Characterization of the rat
liver glucocorticoid receptor purified by DNA-cellulose and ligand affinity
chromatography. J. Biol. Chem. 259, 12915-12924.
8. Stephenson, F. A. and Olsen, R.W. (1982) Solubilization by CHAPS
detergent of barbiturate-enhanced benzodiazepine-GABA receptor
complex. J. Neurochem. 39, 1579-1586.
General Conclusions and Perspectives
119
9. Lang, B., Barnard, E.A., Chang, L.-R. and Dolly, J.O. (1979) Putative
benzodiazepine receptor: a protein solubilized from brain. FEBS Lett. 104,
149-153.
10. Gavish, M., Chang, R.S.L. and Snyder, S.H. (1979) Solubilization of
Histamine H-1, GABA and benzodiazepine receptors. Life Sci. 25, 783-790.
11. Cote, T.E., Gosse, M.E. and Weems, H.B. (1993) Solubilization of high-
affinity, guanine nucleotide-sensitive µ-opioid receptors from 7315c cell
membranes. J. Neurochem. 61, 973-978.
12. Baron, B. and Abood, L.G. (1984) Solubilization and characterization of
muscarinic receptors from bovine brain. Life Sci. 35, 2407-2414.
13. Viel, G.T., Yang, Q., Lundahl, P., Ensing, K. and de Zeeuw, R.A. (1997)
Size-exclusion  chromatographic reconstitution of the bovine brain
benzodiazepine receptor. Effects of lipid environment on the binding
characteristics. J. Chromatogr. A 776, 101-107.
14. Dunn, S.M.J., Martin, C.R., Agey, M.W. and Miyazaki, R. (1989)
Functional reconstitution of the bovine brain GABAA receptor from
solubilized components. Biochemistry 28, 2545-2551.
15. Klein, U. and Fahrenholz, F. (1994) Reconstitution of the myometrial
oxytocin receptor into proteoliposomes. Dependence of oxytocin binding on
cholesterol. Eur. J. Biochem. 220, 559-567.
16. Dickey, B.F., Fishman, J.B., Fine, R.E. and Navarro, J. (1987)
Reconstitution of the rat liver vasopressin receptor coupled to guanine
nucleotide-binding proteins. J. Biol. Chem. 262, 8738-8742.
17. Gioannini, T.L., Fan, L.-Q., Hyde, L., Ofri, D., Yao, Y.-H., Miller, J.M. and
Simon, E.J. (1993) Reconstitution of a purified µ-opioid binding protein in
liposomes: selective, high affinity, GTPγS-sensitive µ-opioid agonist
binding is restored. Biochem. Biophys. Res. Comm. 194, 901-908.
18. Janssen, M.J. (1997) "Development and perspectives of fluorescent receptor




Receptor proteins play an essential role in life. All organisms, from bacteria to
plants, animals and human beings use receptors for their response to (external)
signals. By definition, a receptor is a (macro) molecule which is able to
recognize a distinct chemical entity (e.g. a hormone or neurotransmitter)
amongst many others, and which transduces the information contained within
that entity to the cell, resulting eventually in a response such as activation of an
enzyme, alteration of membrane permeability etc. Most receptors are
transmembrane glycoproteins naturally occurring in or on the cell membranes
of different tissues and organs, although there are also soluble receptors found
in the cytoplasm of the cell, e.g. receptors for steroids and thyroid hormones.
Besides endogenous compounds, poisons and drugs might also interact with a
certain receptor; thereby mimicking or antagonizing the effects normally
triggered by these endogenous molecules. The binding affinity depends on the
potency of the drug. Thus, drugs with a high binding affinity can be
administered in low dosages. The pharmaceutical industry, therefore, is
constantly searching for new drugs with higher potencies, to keep the dosage of
the drug as low as possible in order to minimize the total burden for the body
and eventual side effects.
Ligand binding assays, including immunoassays and receptor assays, take
advantage of the highly selective interaction between a binding protein (an
antibody in the case of immunoassays or a receptor when receptor assays are
used) and a ligand. Although immunoassays are widely used and are very
sensitive in the quantitation of a variety of ligands, receptor assays can be used
not only to determine the concentration of a ligand, but also its affinity for the
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receptor. Besides, the raising of antibodies is a costly and laborious process,
whereas receptors can be isolated in large amounts from animal tissue, obtained
e.g. from the slaughterhouse, without much effort. The principle of the receptor
assay is that, under well-controlled conditions, the receptors are incubated in
vitro with a certain amount of labeled ligand and a (unknown) amount of
analyte, which has a similar affinity for the same receptor. The amount of
labeled ligand ultimately bound to the receptor depends on the concentration of
analyte present in the sample. Thus, a low concentration of analyte will result
in a high occupancy of the receptors by the labeled ligand, whereas at a high
concentration of analyte only a small fraction of the labeled ligand will be
bound to the receptors.
Two types of receptor assays can be distinguished:
1. Saturation binding experiments, in which constant amounts of receptors
are incubated with increasing concentrations of labeled ligand. In this type
of experiment the receptor binding sites will be occupied by the labeled
ligand until, at a high concentration of labeled ligand, all receptors contain
a bound ligand and, thus, are saturated. From these experiments the affinity
(Kd) of the ligand and the maximum amount of binding sites (Bmax) can be
determined.
2. Inhibition binding experiments, in which constant amounts of receptors
are incubated with a constant amount of labeled ligand and varying
amounts of analyte. The (unlabeled) analyte will compete with the labeled
ligand for the same receptor binding site. Increasing the concentration of
analyte will result in lowering of the amount of labeled ligand bound to the
receptor. Besides the Kd, also the IC50 (the concentration of analyte capable
of displacing 50% of the maximum amount of bound labeled ligand) can be
determined from these experiments.
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Because of the low amounts of ligand and/or analyte (working levels typically
in the nM - pM range), a label exhibiting a strong analytical signal is needed for
sensitive detection of the bound ligand. So far, radioactive labels were used on
many occasions, because of the high sensitivity and relative easy in obtaining
these labels. The use of radioactivity, however, has several obvious
disadvantages. Therefore, several attempts have been made recently in which
fluorescent-labeled ligands were constructed. However, coupling of a large
fluorescent group can easily result in a reduction of the affinity of the
fluorescent-labeled ligand for its receptor, due to steric hindrance. Moreover,
many positions on the ligand might be involved in the actual receptor binding
and can therefore not be used for the coupling with the fluorescent moiety. The
selection of a suitable ligand, an adequate  fluorescent moiety and the
development of the coupling procedure, is not an easy task and usually a
process of trial and error.
This thesis describes the development of a novel fluorescent receptor assay for
benzodiazepines. Instead of using a fluorescent-labeled ligand, the receptors
were incorporated into fluorescent liposomes. To accomplish this, the receptor
was solubilized from calf brain membranes and reconstituted in liposomes
made of crude soybean lipids and fluorescent lipids. Furthermore, a ligand was
immobilized to a microtiter plate to which the proteoliposomes containing the
benzodiazepine receptors could bind. After washing the plate with ice-cold
buffer, the bound proteoliposomes could be detected in the microtiter plate
using a fluorescence plate reader. When analyte was added during the
incubation, part of the receptors were displaced from the immobilized ligand
resulting in a lower fluorescence signal after the washing step. Since many
fluorescent lipids were present per single receptor protein, resulting in an
amplification of the fluorescence signal, a gain in sensitivity was achieved, as
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compared to classical fluorescent-ligand assays, in which only one label per
receptor-ligand interaction is present.
The benzodiazepine receptor was selected as a model system, because of the
experience present in our research group with the development of a
radioreceptor assay for benzodiazepines and, recently, the development of a
non-radioactive receptor assay for benzodiazepines, utilizing a fluorescent
ligand. Besides, benzodiazepines are widely prescribed by physicians. A
sensitive assay method is therefore necessary, e.g. for the screening of new
drugs, for the testing of drugs of abuse and in clinical and forensic toxicology.
In Chapter 1 the principle and theory of receptor assays is explained and a
comparison with immunoassays is made. Methodological aspects, such as the
selection and preparation of receptor material, the choice of the labeled ligand
(radiolabels versus fluorescent labeled ligands) and methods for the separation
of bound and free fractions of the ligand are discussed. Finally, different
aspects of the solubilization of receptors (and membrane proteins in general)
and the reconstitution of these receptors into lipid vesicles are described.
Chapter 2 describes the solubilization of the benzodiazepine receptor. To a
crude calf brain homogenate, a suitable detergent was added. Sodium
deoxycholate was chosen as the detergent and factors such as the concentration
of detergent, de pH of the buffer and the ionic strength of the buffer, more
specifically the addition of KCl, were optimized. To minimize the negative
effects caused by the detergent, such as irreversible denaturation of the
membrane proteins, the detergent concentration should be kept as low as
possible. Although the binding characteristics of the solubilized receptors for
the radiolabel were diminished compared to the membrane homogenate, as
shown by the affinity constant Kd of 2.7 nM and a Bmax of 0.40 pmol/mg
protein for the solubilized preparation compared to a Kd of 1.46 nM and a Bmax
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of 0.85 pmol/mg protein for the membrane-bound receptors, the solubilized
receptor suspension was found  to be a good starting point for further
experiments.
A better environment for receptors than just aqueous solubilization is a
biological membrane, in which lipids surround, and stabilize, the membrane
proteins. To mimic this situation, the solubilized benzodiazepine receptors were
reconstituted into liposomes as described in Chapter 3. Solubilized lipids were
mixed with the solubilized receptors and the detergent was removed by size-
exclusion chromatography (gel-filtration), after which the proteoliposomes
were formed. The mean size of the formed proteoliposomes was found to be 75
nm. To determine to what extent the choice of the lipid influences the binding
characteristics of the reconstituted benzodiazepine receptor, several types of
lipids, and mixtures thereof, were used in the reconstitution experiments.
Asolectin, a crude soybean extract containing a mixture of several lipids, was
found to be most suitable. The Kd was similar to that of the solubilized
receptor, but the Bmax was lowered, suggesting a loss in total binding sites or
inactivation of part of the receptors. Yet, freezing and thawing led to an
increase in the Bmax values. The mean size of the proteoliposomes was doubled
to 150 nm after the freezing and thawing cycle. The enlargement of the
proteoliposome particle size might cause this increase in the Bmax, with the
curvature of the membrane playing a role in the functioning of the membrane
proteins. Alternatively, the receptors were better inserted in the membrane
during the freeze/thawing cycle, leading to activation of previously inactive
receptor proteins.
The long-term stability of the proteoliposomes was assessed through storage of
the proteoliposome suspension during a 2 month period at 4°C, −20°C or
−80°C. Though storage at 4°C led to inactivation of the reconstituted
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benzodiazepine receptor within one week, full activity of the receptors was
maintained when stored at −20°C or −80°C.
Besides asolectin, fluorescent lipids could be co-incorporated in order to obtain
fluorescent-labeled liposomes or proteoliposomes, as shown in Chapter 4.
Three types of fluorescent lipids were used for these experiments, and
fluorescein-DHPE was found to be suitable for strong labeling of the
(proteo)liposomes. At a concentration of 250 µg fluorescein-DHPE per 150 mg
total lipids, a 100,000-fold dilution of the liposomes suspension could be used
in which the fluorescence signal was still significantly above background
values. This is important since low amounts of proteoliposomes should be
detectable when they are used in a fluorescent receptor assay.
Chapter 5 describes the immobilization of a suitable benzodiazepine ligand
(didesethylflurazepam) to a microtiter plate. A modified radioreceptor assay
showed that the principle of using proteoliposomes containing the
benzodiazepine receptor in a microtiter plate containing immobilized ligand
was valid. Because the binding between the receptor and the immobilized
ligand takes place in a very small volume, near the walls of the plate, an
increase in the sensitivity of the assay was observed.
In Chapter 6 the development of the novel fluorescence receptor assay in
microtiter plates is described. The fluorescent proteoliposomes, containing the
benzodiazepine receptor, were added to the microtiter plate with the
immobilized ligand. Addition of samples with increasing concentrations of
analyte (lorazepam) led to displacement of the receptors from the immobilized
ligand, in such a way that a clear-cut sigmoid relation was found between
receptors found in the solution and the amount of analyte added. A factor 30 in
sensitivity was gained using this assay compared to the traditional
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radioreceptor assay. It can be expected that even higher sensitivities will be
achieved when the assay is further optimized and validated.
Chapter 7, finally, gives some general conclusions about the work presented in
this thesis, and gives recommendations for future experiments. Since protocols
for the solubilization and reconstitution of many other types of receptors are
available, and methods for immobilization of ligands for these receptors to
solid phases are also described in the literature, it is expected that the novel
fluorescent receptor assay approach as developed in this thesis will be generally
applicable for other classes of pharmacologically active substances.   
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Samenvatting
Receptoren vervullen een belangrijke taak in alle hogere levende organismen.
Deze eiwitten zijn of te vinden in het omhulsel van een cel, het zogenaamde
celmembraan, of ze zijn aanwezig in het binnenste (vloeibare deel) van de cel,
het cytoplasma. Receptoren hebben de eigenschap dat ze uit een grote
hoeveelheid verschillende moleculen één, voor de receptor specifiek molecuul,
of een groep van zeer verwante moleculen kunnen herkennen en binden,
waarna dit een bepaalde reactie in de cel tot gevolg heeft. Bij mensen worden
velerlei processen in het lichaam op deze wijze door receptoren gecontroleerd,
zoals de bloeddrukregeling, de hormoonhuishouding en de signaaloverdrachten
in de hersenen. Echter, lichaamsvreemde stoffen zoals vergiften en
geneesmiddelen kunnen ook een binding aangaan met een bepaalde receptor,
mits het vergift of geneesmiddel sterk lijkt op het lichaamseigen (endogeen)
molecuul wat normaliter aan deze receptor bindt. Zoals verwacht kan worden
maakt de farmaceutische industrie dankbaar gebruik van deze kennis. Immers,
wanneer men weet wat de functie van een bepaalde receptor is, (bijvoorbeeld
bloeddrukregulatie) en de structuur van het endogene molecuul is tevens
bekend, dan kan een geneesmiddel worden ontworpen, die (zeer) sterk aan het
receptor eiwit bindt, waardoor het gewenst effect bereikt wordt (zoals
bloeddrukverlaging). Om precies te zijn, geneesmiddelen kunnen zó worden
ontworpen, dat ze het normale effect van de receptoren kunnen imiteren dan
wel verhinderen.
De binding, uitgedrukt in de bindingsaffiniteit, is een maat voor de sterkte van
het geneesmiddel. Dit wil zeggen dat geneesmiddelen die een hoge
bindingsaffiniteit bezitten in lage doseringen kunnen worden toegediend. Het
spreekt dus vanzelf dat een zo hoog mogelijke affiniteit van een geneesmiddel
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voor een specifieke receptor gunstig is, aangezien de dosering dan laag kan
blijven, waardoor de totale belasting voor het lichaam minimaal is.
De receptoren die benodigd zijn voor het experimenteel werk, kunnen vrij
eenvoudig verkregen worden uit dierlijk materiaal, hetzij slachtafval dan wel
proefdieren. In de reageerbuis (in vitro) vindt de binding plaats tussen een
bepaalde hoeveelheid receptoren en de chemische verbinding (ook wel ligand
genoemd) hetgeen, na scheiding van het receptor-gebonden en vrije deel van
het ligand, gemeten kan worden. Deze zogenaamde receptor assays zijn uniek
als analyse methode, aangezien ze zowel de hoeveelheid van een bepaalde
verbindingen kunnen bepalen, maar ook de mate van binding; de affiniteit.
Twee soorten receptorassays kunnen worden onderscheiden:
1. Verzadigingsexperimenten, waarbij, in afzonderlijke reageerbuizen, aan
een constante hoeveelheid receptoren een steeds hogere concentratie
gelabelde (eenvoudig te detecteren) ligand wordt toegevoegd. Bij de
hoogste concentraties ligand zal er verzadiging van de receptoren te zien
zijn, hetgeen wil zeggen dat alle bindingsplaatsen bezet zijn met ligand. Uit
deze experimenten kunnen zowel de bindingsaffiniteit van het ligand (Kd)
en de maximale hoeveelheid bindingsplaatsen (Bmax) bepaald worden.
2. Verdringingsexperimenten, waarbij een constante hoeveelheid receptoren
wordt geςncubeerd met een constante hoeveelheid gelabeld ligand en een
hoeveelheid ongelabeld ligand (analiet). Wanneer de concentratie van het
analiet toeneemt zal het uiteindelijk het gelabelde ligand verdringen. Met
andere woorden, bij lage concentraties analiet zal het grootste deel van het
gelabelde ligand aan de receptoren gebonden zijn (sterk detectiesignaal)
terwijl bij een hoge concentratie analiet de hoeveelheid gebonden,
gelabelde ligand minimaal is (zwak detectiesignaal). Uit deze experimenten
kan ook de Kd bepaald worden, maar ook een andere veel gebruikte
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parameter: de IC50, de hoeveelheid analiet die in staat is 50% van de
maximale hoeveelheid van het ligand kan verdringen.
Om de binding tussen ligand en receptor te kunnen meten moet het ligand een
geschikt label bevatten dat zeer gevoelig gemeten kan worden. Tot dusverre is
er meestal gebruik gemaakt van radioactief gelabelde liganden, aangezien
radioactiviteit relatief eenvoudig, nauwkeurig en zeer gevoelig te meten valt. Er
kleven echter diverse nadelen aan het gebruik van radioactiviteit, waardoor de
vraag naar niet-radioactieve detectiemethoden steeds groter wordt.
Een goed alternatief voor radioactiviteit is fluorescentie. Fluorescent-gelabelde
liganden kunnen echter een (sterk) verminderde affiniteit hebben voor de
receptor, aangezien een vrij grote fluorescente groep aan het ligand moet
worden gekoppeld, hetgeen de receptor binding kan (ver)hinderen.
Dit proefschrift beschrijft de ontwikkeling van een nieuw type fluorescente
receptor assay voor benzodiazepines. Het labelen van een ligand met een
fluorescente groep werd vermeden door de receptoren in te bouwen in
fluorescente liposomen (vetzuurbolletjes). Hiervoor was het noodzakelijk de
receptoren (en een deel van de overige aanwezige eiwitten) te isoleren uit het
membraan, waarna geschikte vetzuren werden toegevoegd en de (fluorescent-
gelabelde) liposomen werden gemaakt. Het ligand werd vervolgens aan een
geschikt dragermateriaal gekoppeld. Dit zogenaamde geïmmobiliseerde ligand
was in staat de liposomen met receptoren te binden. Na een simpele wasstap,
om de vrije fractie gelabelde liposomen van de gebonden fractie te scheiden,
kon de gebonden hoeveelheid fluorescentie direct in het dragermateriaal
gemeten worden. Een oplopende concentratie benzodiazepine in het monster
was in staat competitie aan te gaan met het geïmmobiliseerde ligand, waardoor
laatstgenoemde verdrongen werd van de receptor bindingsplaats. Met andere
woorden, een hoge concentratie benzodiazepines in het monster resulteerde in
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een lage hoeveelheid fluorescentie dat uiteindelijk op het dragermateriaal werd
gemeten, terwijl een lage concentratie benzodiazepines in het monster een sterk
fluorescentie signaal te zien gaven.
Wanneer gelabelde liganden worden gebruikt, is er per ligand-receptor binding
1 detecteerbare groep aanwezig. In de door ons ontwikkelde methode kunnen
vele fluorescente vetzuren in hetzelfde liposoom ingebouwd worden, waardoor
per ligand-receptor binding een groot aantal detecteerbare groepen aanwezig
zijn. Dit resulteert in een versterking van het fluorescentie-signaal waardoor de
gevoeligheid van de nieuw ontwikkelde receptor assay groter is dan bestaande
assays.
De benzodiazepine receptor is als model gekozen, vanwege de ervaringen die
onze onderzoeksgroep in de afgelopen jaren heeft opgedaan met zowel de
ontwikkeling van een radioreceptor assay (dus gebruik makend van een
radioactief isotoop voor detectie) voor benzodiazepines, als ook de
ontwikkeling van een niet-radioactieve receptor assay voor benzodiazepines,
waarbij een fluorescente groep aan het ligand werd gekoppeld. Bovendien zijn
benzodiazepines (bijvoorbeeld Valium®) een belangrijke groep
geneesmiddelen, aangezien ze zeer veelvuldig door de arts worden
voorgeschreven. Een gevoelige assay methode is derhalve gewenst, niet alleen
om de geschikte dosis te kunnen instellen (therapeutic drug monitoring) en
voor screening van nieuwe geneesmiddelen, maar ook in de klinische en
forensische toxicologie en bij het onderzoek naar geneesmiddelenmisbruik
(o.m. drug abuse testing, verkeerstoxicologie, workplace testing).
Hoofdstuk 1 geeft een inleiding over het principe van receptor assays, waarbij
tevens wat dieper wordt ingegaan op de theorie. Ook is er een vergelijking
gemaakt met een ander soort ligand-binding assay, de immunoassay.
Methodologische aspecten, waaronder de selectie en bewerking van receptor
materiaal, de keuze van het gelabelde ligand (radiolabels en fluorescent-
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gelabelde liganden) en de keuzemogelijkheden om de vrije en gebonden fractie
ligand te kunnen scheiden worden hier eveneens besproken. Daarnaast wordt er
aandacht besteed aan de mogelijkheden voor solubilisatie (oplosbaar maken)
van membraaneiwitten en de reconstitutie (inbouwen in liposomen) van de
receptoren.
In Hoofdstuk 2 wordt de solubilisatie van de benzodiazepine receptor
beschreven. De receptoren, die in grote membraanfragmenten zitten, werden
met behulp van een detergens van de lipiden (vetzuren) gescheiden.
Natriumdeoxycholaat werd gekozen als detergens, en factoren zoals de
concentratie detergens, de pH van de buffer en de ionensterkte (toevoeging van
KCl) werden geoptimaliseerd. Hoewel de bindingseigenschappen van de
gesolubiliseerde receptoren voor het radiolabel [3H]flunitrazepam ([3H]FNM)
wel veranderen (een affiniteitsconstante (Kd) van 2.7 nM en een maximale
hoeveelheid bindingsplaatsen (Bmax) van 0.40 pmol/mg eiwit, vergeleken met
een Kd van 1.46 nM en een Bmax van 0.85 pmol/mg eiwit voor membraan-
gebonden receptoren) is deze gesolubiliseerde receptorsuspensie zeer zeker
geschikt als uitgangsmateriaal voor verdere experimenten.
Aangezien de toevoeging van detergentia aan membranen een negatief effect
kan hebben op de werking van de membraaneiwitten dient de concentratie van
het detergens zo laag mogelijk te worden gehouden.
In Hoofdstuk 3 wordt de reconstitutie van gesolubiliseerde receptoren in
liposomen beschreven. Gesolubiliseerde lipiden werden gemengd met de
gesolubiliseerde receptoren en, via gel-filtratie, werden proteoliposomen
(liposomen met eiwitten) gevormd. De gemiddelde grootte van de gevormde
proteoliposomen was 75 nm. Onderzocht werd welke lipiden van belang zijn
voor behoud van de bindingseigenschappen van de benzodiazepine receptor.
Een mengsel van lipiden (asolectine, een extract van lipiden van de soja boon),
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bleek de bindingseigenschappen het minst te verstoren. De Kd bleef vrijwel
onveranderd, maar de Bmax nam wel verder af, hetgeen wijst op verlies van de
totale hoeveelheid bindingsplaatsen, dan wel inactivatie van een deel van de
receptoren. Na een cyclus van vriezen (−70°C) en ontdooien (+20°C) werd er
een stijging in de Bmax waargenomen. Hoewel de gemiddelde grootte van de
liposomen met een factor twee toeneemt tot 150 nm, waardoor het grote
receptor complex wellicht beter kan functioneren, kan het ook zo zijn dat de
receptor gedurende de vries/dooi cyclus beter de gelegenheid krijgt zich goed
in het membraan te positioneren. Een deel van de receptoren die voor de
vries/dooi cyclus inactief was, werd derhalve actief na deze cyclus.
Om de stabiliteit van de gereconstitueerde receptorsuspensie vast te stellen
werd deze voor een langere periode bewaard bij 4°C, −20°C en −80°C. Hoewel
de receptoren die bij 4°C bewaard werden al na een week vrijwel inactief
waren, bleek opslag bij −20°C en −80°C nauwelijks van invloed op de activiteit
gedurende twee maanden.
Een betere omgeving voor de receptoren is een membraan, waarbij lipiden de
receptoreiwitten omhullen en stabiliseren.
Door naast asolectine ook fluorescente lipiden toe te voegen aan de
gesolubiliseerde receptoren, worden na reconstitutie fluorescent gelabelde
proteoliposomen gevormd, hetgeen beschreven wordt in Hoofdstuk 4. Drie
verschillende fluorescente lipiden zijn gebruikt tijdens de experimenten,
waarbij is gebleken dat fluoresceine-DHPE geschikt is om de liposomen sterk
te labelen. Bij een concentratie van 250 µg fluoresceine-DHPE per 150 mg
lipiden kon de proteoliposoom suspensie 100.000 keer verdund worden,
waarbij het fluorescentie signaal nog steeds meetbaar was. Dit is belangrijk
aangezien er in de te ontwikkelen receptor assay in een aantal gevallen (waarbij
de concentratie analiet in het monster hoog is) slechts een gering aantal
gelabelde proteoliposomen moet kunnen worden gemeten.
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In Hoofdstuk 5 wordt de koppeling van een geschikte benzodiazepine
(didesethylflurazepam) aan een microtiterplaat beschreven, waarna met een
aangepaste radioreceptor assay het principe werd aangetoond dat
proteoliposomen (met de benzodiazepine receptor) aan geïmmobiliseerde
liganden kunnen binden. Doordat de binding tussen geïmmobiliseerd ligand en
de receptor  slechts in een zeer klein gebied plaats heeft (namelijk de wanden
van de microtiterplaat), werd een verbetering van de gevoeligheid van de assay
waargenomen.
In Hoofdstuk 6 wordt de ontwikkeling van de nieuwe fluorescente receptor
assay in microtiterplaten beschreven. De fluorescente proteoliposomen, die de
benzodiazepine receptor bevatten, werden toegevoegd aan de microtiterplaten
met geïmmobiliseerd ligand. Toevoeging van monsters met oplopende
concentraties (ongelabelde) analiet resulteerde in verdringing van de
proteoliposomen van geïmmobiliseerd ligand. Een factor 30 winst in
gevoeligheid vergeleken met traditionele radioreceptor assays werd gevonden.
Verwacht wordt, dat wanneer de assay verder geoptimaliseerd en gevalideerd
is, een nog hogere gevoeligheid bereikt kan worden.
Hoofdstuk 7, tenslotte, geeft de algemene conclusies over de in dit proefschrift
beschreven werk, en geeft enkele aanbevelingen voor toekomstige
experimenten. Aangezien de koppeling van liganden aan dragermaterialen en
solubilisatie- en reconstitutie protocollen voor diverse andere receptoren in de
literatuur zijn beschreven, is de verwachting gerechtvaardigd dat een
soortgelijke fluorescente receptor assay als hier beschreven voor de
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